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 Given the inherent dangers associated with racemic pharmaceuticals, exhaustive 
investigations of techniques designed to separate enantiomers have been performed.  Most 
methods are intrinsically expensive, consume vast quantities of organic solvent, and involve 
combinations of time consuming crystallization and/or chromatographic procedures.  This 
dissertation reports herein the first step towards using pressure as a readily controllable variable 
during enantiomeric separation of racemic ibuprofen in liquid and supercritical carbon dioxide.  
Custom synthesized, CO2 soluble and partially soluble resolving agents are added to the fluid 
phase to promote formation of diastereomeric salt pairs, which exhibit differences in their 
chemical and physical properties, such as solubility.  Unlike enantiomers, which exhibit nearly 
identical solubility in carbon dioxide, separation of salt pairs may be accomplished by selective 
extraction at designated pressures due to the differences in their phase behavior in CO2.  Because 
formation of ion pair complexes occurs readily in media of low polarity, supercritical carbon 
dioxide offers an attractive alternative to traditional organic media.  
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 1.0  INTRODUCTION 
 
 
 
 
1.1  Chirality 
 
 
 
In all biological systems homochirality is predominant and has been preserved since the 
beginning of evolutionary time.  Homochirality refers to the spatial configuration of molecules, 
such as D- and L- amino acids, which are either produced by biological organisms or 
synthetically created. (1)*  This spatial configuration is vital to biological activity because 
asymmetry dominates at the molecular level.  From Pasteur’s first studies involving 
biotransformations to Fisher’s “lock – and –key” concept, our understanding of biomolecular 
interactions have grown, resulting in the development of highly specific pharmaceuticals.   
By definition, a chiral material is one which lacks reflectional symmetry, i.e. exhibits a 
non-superimposable mirror image structure, and is termed as being “handed”.  The most 
common chiral compounds which exist are enantiomers.  These materials are typically 
characterized by an asymmetric, tetrahedral carbon atom located at the center of the molecule.  
These molecules can exist as stable, observable stereoisomers if their energy barrier of 
conversion exceeds 80 KJ/mole.  In addition, compounds which exist as enantiomers have nearly 
identical physical and chemical properties in an achiral environment, making their resolution into 
individual components challenging. 
 
 
 
 *Parenthetical references placed superior to the line of text refer to the bibliography 
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 When these enantiomers are present in equimolar amounts within a mixture, the resultant 
mixture is termed racemic.  These preparations are optically inactive, because the net rotation of 
plane polarized light is negated by the equal concentrations of each enantiomer.  The first 
successful attempt to resolve enantiomers from their racemic mixture was performed by Louis 
Pasteur, in which he manually resolved a racemic mixture of sodium ammonium tartrate into its 
individual enantiomers. (2) 
Diastereoisomers are non mirror image stereoisomers that possess more than one 
asymmetric center.  Unlike enantiomers, diastereomers may be individually isolated because 
differences exist in their physical and chemical properties, such solubility and melting point. (2)  
Enantiomers may be transformed into diastereomers by either covalently or non-covalently 
coupling the enantiomers of a racemic mixture to another chiral molecule possessing at least one 
asymmetric center.  This methodology defines a separation route by which two previously 
inseparable materials may be isolated by conventional techniques. 
 
 
 
  
1.2  Pharmaceutical Trends 
 
 
 
 The importance of determining the pharmacological activity of each component in a drug 
has now gained full acceptance as shown by the substantial number of single isomer 
pharmaceuticals entering the commercial market.  The motivation for this single isomer trend has 
been provided in part by the FDA and in part by the production of a host of pharmaceuticals 
previously protected by 17 – 20 year patent production laws.  Concerns which the FDA are 
requiring pharmaceutical producers to address include: 
 2
 • pharmacological properties of the individual enantiomers and of the racemic 
mixture 
• assays which determine enantiomeric purity 
• the need to produce as a single isomer 
• economic incentives to develop separation methods for existing racemic mixtures 
 
Those particular chiral drugs, whose patents are expiring, are attracting a multitude of 
oversea producers.  This would provide pricing competition and increase the “generic brand” 
availability from producers with large scale capacities. (3) 
 Chirally active drugs also represent a large share of the pharmaceutical market.  In 1996 
chiral drugs composed $73 billion dollars of the market, which was an 18.6% increase from the 
previous year.  Chiral bulk active drugs used in producing dosage forms were valued at $13.5 
billion dollars.  Technology Catalysts International has estimated that by the year 2000, dosage 
formulations will exceed $90 billion. (3)  Table 1 outlines the sales figures and predicted growth 
rates for the three top categories of drugs produced in the United States. 
  There does exist a small minority of these drugs, which are eligible for a racemic switch 
as shown in Figure 1.  A racemic switch is a reprocess and reformulation of a racemic mixture, 
previously approved by the FDA, into its single isomer product.  As shown in Table 2, a host of 
common name brand pharmaceuticals are eligible or are currently undergoing a racemic switch.  
It is important to note the number of candidates within the anti-inflammatory and analgesic 
category. 
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Table 1  Sales Figures and Predicted Growth Rates  (3) 
 
 
Chiral drugs are $73 billion global market 
Sales 
  
Bulk active 
1996 ($ millions) 
       Dosage Form ($ millions) 
 
   1996                            2000 
Predicted average 
annual growth 
rate 
Category 
Antibiotics      $ 4,880 $ 19,527 $ 20,905             1.7% 
Cardiovascular         2,040    17,530    19,535             2.7 
Hormones- 
     Endocrinology 
 
        1,340 
 
    8,006 
 
   11,950 
 
          10.5 
Cancer         1,310     7,547     8,390             2.7 
Hematology         1,025     5,199     5,050            -0.7 
 
Central Nervous 
System 
     
         715 
    
   4,065 
    
   7,505 
 
          16.6 
Vaccines          730    3,970    4,550            -3.5 
Antivirals          300    1,815    4,420           25.0 
Organ Rejection          295    1,475    1,650            2.8 
Respiratory          244    1,201    1,240            0.8 
Analgesics          355       895     815           -2.3 
 
Ophthalmic          125       675     630           -1.7 
Benign Prostate 
Hyperplasia 
 
          77 
 
      450 
 
    750 
 
          13.6 
Dermatology           46       545     675             5.5 
Anesthesia             0           0      60             na 
Other             0           0   2,000             na 
Total 
 
     $ 13,482 
 
$ 72,900 
 
$ 90,025 
 
            5.4% 
Table reproduced from S.C. Stinson (3) 
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 Table 2  Candidates for Racemic Switches (4) 
 
 
Cardiovascular  Anti-inflammatory and analgesic 
Acebutolol Alprenolol Cicloprofen Corticosteroids 
Atenolol Betaxolol Dihydroxythebaine Feribufen 
Bisoprolol Bopindolol Fenoprofen Flurbiprofen 
Bucumolol Bufetolol Ibuprofen Indoprofen 
Bufuralol Bunitrolol Ketoprofen Minoxiprofen 
Bupranolol Butofilolol Pirprofen Suprofen 
Carazolol Carvedilol Triamcinolone  
Disopyramide Dobutamine  
Indenolol Mepindolol Anticancer 
Meupranolol Metoprolol Cytarabine  
Nadolol Nicardipine  
Oxprenolol Pindolol Antibitoics, anti-infectives, and anti-virals 
Propranolol Sotalol Ciprofloxacin Norfloxacin 
Toliprolol Verapamil Ofloxacin  
Xibenolol    
 
Central Nervous System  Hormones and genitourinary 
Dobutamine Fluxetine Benzyl glutamate Butoconazole 
Ketamine Lorazepam Calcitonin Estradiol 
Meclizine Oxaprotiline Fluorogestone Gonadorelin 
Phenylpropanolamine Thioridazine Norgestrel Testosterone 
Polychloramphetamine Tomoxetine  
Toloxatone Viloxazine Antihistamines and cough-cold 
 Astemizole Terfenadine 
Respiratory   
Albuterol Metaproterenol   
Terbutaline    
Source: Technology Catalysts International 
Table reproduced from S. Ahuja (4) 
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 2.0  BACKGROUND AND LITERATURE REVIEW 
 
 
 
 
2.1  Ibuprofen as a Model Compound 
 
 
 
In the anti-inflammatory class of pharmaceuticals, ibuprofen is an interesting example of 
one which is still sold as a racemic mixture.  The single isomer product has a greater commercial 
value than the racemic mixture, but production has been limited by legal and process difficulties.  
In addition, ibuprofen is the one member from the NSAID family which has proven to be the 
most challenging to enantiomerically purify.  A large research investment has been made in order 
to develop techniques specific to ibuprofen.  Out of this research has come information used to 
develop methods from simple crystallizations to complex membrane separations. 
 For this research project, ibuprofen was chosen as a model compound for the following 
reasons; 
• A wealth of information concerning its physical and chemical properties, 
reactivity, and production is readily available. 
• It is a simple and stable molecule as shown below in Figure 2. 
• Development of new separation methods for this and related molecules is still a 
large area of pharmaceutical research. 
• Recent attempts have been made to enantiomerically separate ibuprofen in 
supercritical carbon dioxide. 
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Figure 2  Chemical Structure of Ibuprofen 
 
 
 
 
2.2  Chromatographic Separation Methods 
 
 
 
  Presently, there are a variety of resolution techniques by which the enantiomers of 
ibuprofen are separated.  Each method introduces an asymmetric environment either 
intramolecularly, in which a diastereomeric pair is chemically produced to interact with a 
nonchiral medium, or intermolecularly, where the underivatized free acid interacts with a chiral 
medium. (5)  For each method, several advantages and disadvantages prevail depending upon 
factors such as time, purity, chemical processing, and inherent side reactions.  These factors have 
all contributed to the lack of a universal enantiomeric separation regime for racemic ibuprofen. 
  The most common method to date for the enantiomeric resolution of ibuprofen 
enantiomers and, in general chiral materials, is high performance liquid chromatography.  
Construction of a chiral stationary phase or pre-derivatization of the individual enantiomers to 
produce the diastereomeric pair, are the two important techniques that are employed.  Though 
these techniques vary from normal to reverse phase and utilize a variety of detector systems, the 
separations achieved thus far are similar.   
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  There are extensive reports in the literature concerning the pre-derivatization technique. 
(7,8,9,10,11,12,13)  In most instances ethyl chloroformate is used to couple a chiral ligand to the 
racemic enantiomers in order to produce the diastereoisomeric pair.  A separation factor, which is 
defined as the ratio of the time required for the last enantiomer to elute divided by the first 
enantiomer to elute, is used to evaluate the performance of the technique.  Separation factors of 
1.09 to 1.12 for ibuprofen were reported, thus yielding an acceptable separation.  (In the literature, 
a separation factor in excess of 1.2 is desirable.)  Though the enantiomers of ibuprofen were 
resolved in under 20 minutes, there are inherent drawbacks to this method.  These drawbacks 
include: 
• The rates of formation for the diastereoisomer pair may be different, leading to an 
incorrect ratio of the two enantiomers. 
• Impurities within the reaction mixture could lead to a multiple number of 
diastereoisomeric pairs. 
• Racemization may occur and its extent is dependent upon the coupling agent and 
reaction solvent.  
• A chemical, covalent bond is formed between the coupling agent and ibuprofen, 
which is difficult to disassociate to recover the free acid of ibuprofen. (9) 
 
 The deficiencies in the pre-derivatization method prompted investigators to develop a 
technique by which ibuprofen would remain chemically unmodified.  Instead, a column which 
possessed a chiral packing material was employed. (14,15,16,17,18,19)  These chiral packing materials 
most often are composed of derivatives of cellulose, cyclodextrins, proteins, and amino acids. (14)  
Base line resolution of enantiomeric ibuprofen has been successful in under 30 minutes.  The 
separation factors, though, exhibited a column dependent broad range from 1.08 for the 
cyclodextrin based columns, 1.06 for the Pirkle silica gel modified columns, and a high of 1.29 
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 for modified ovomucoid columns.  The disadvantage of this method is that there appears to be no 
universal chiral column and analysis conditions.  In addition, large volumes of organic based 
mobile phase are required for component elution, and this volume of solvent must be evaporated 
in order to recover the free acid of ibuprofen.  Obtaining ibuprofen with the minimal solvent 
contamination as required by the FDA becomes more costly as the amount of ibuprofen processed 
increases.  This method, however, is still preferred to pre-derivatization since the number and 
availablility of different chiral columns commercially available has increased.  
 
 
 
 
2.3  Other Methods 
 
 
 
 Another method of producing enantiomerically pure ibuprofen is selective enzymatic 
esterification using lipases.  Taking advantage of the naturally inherent selectivity of the 
enzyme’s active site, reactive discrimination occurs between the enantiomers in the racemic 
mixture.  Though not exclusive, one enantiomer in general “fits” better in the active site and is 
therefore converted to its corresponding ester at a higher rate. (20)  Rantakyla and Aaltonen 
esterified racemic ibuprofen with n-propanol in supercritical carbon dioxide by means of an 
immobilized lipase.  The resulting enantiomeric excess was approximately 70% of the S(+) 
enantiomer with 15 to 20 % conversion. (6)  This process is dependent upon a number of variables 
including optimum temperature, ibuprofen and alcohol concentration, pressure, water content, and 
enzymatic lifetime.  
The advantage of this method is the high enantiomeric excess, resulting from the inherent 
selectivity of the enzyme.  The enzyme is reusable and the products from the reaction are easy to 
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 separate.  The disadvantages of this method are related to the number of system parameters which 
must be optimized for the enzyme, and the selectivity of the system is limited by the extent of 
conversion. ( 21) 
 Gas chromatography, mass spectrometry, electrochromatography, capillary 
electrophoresis, and nuclear magnetic resonance have also been utilized as potential analytical 
techniques in enantiomeric separations of ibuprofen. (22,23,24,25,26)  These methods have proven of 
less utility due the inability to achieve baseline resolutions or inability to recover the free acid of 
ibuprofen after separation.  In addition, the effectiveness of high performance liquid 
chromatography has masked advanced development of these methods. 
 A recent development in the separation of ibuprofen enantiomers has been in supercritical 
fluid chromatography. (27,28,29,30)  Ibuprofen has been shown to exhibit solubility in supercritical 
carbon dioxide at optimum conditions of 70°C and a supercritical carbon dioxide density of 0.7 
g/ml. (29)  SFC behaves similar to normal phase high pressure liquid chromatography, but can be 
run at 3 to 10 times faster than normal phase HPLC.  In addition, SFC does not produce problems 
of column deactivation, long equilibration times, and leaching of a chiral constituent. (27)  SFC, 
when performed with carbon dioxide, also provides an environmentally sound separation 
technique. 
 SFC utilizes a chiral column and a mobile phase, which usually consists of a combination 
of carbon dioxide and a polar modifier such as methanol or tetrahydrofuran.  A separation factor 
for ibuprofen of 1.14 was obtained with baseline resolution. (27)  One advantage that traditional 
HPLC exhibits over SFC is peak shape and resolution.  Separations in SFC tend to produce peaks 
in which peak tailing is evident.  This is thought to be attributed to hydrogen bonding interactions 
with the chiral packing of the column. (28)  Despite this disadvantage, SFC is attractive due to the 
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 use of a benign mobile phase and the speed at which separations may be performed.  
Unfortunately, this technique has not been well received as a prep scale separation method. 
 
 
 
 
2.4  Physical Separation Methods 
 
 
 
 All of the previous separation techniques utilize a chromatographic methodology in some 
aspect.  The instrumentation and processing would be expensive on an industrial scale, and the 
need for a cheap and reliable method is evident.  Crystallization has been the predominant 
separation technique to resolve an enantiomeric mixture into its individual isomers on the 
industrial scale.  There are three primary methods of crystallization for enantiomeric resolution.  
These include: 
• Preferential crystallization – stereospecific growth of each individual isomer in 
two different crystallizers from solution.  This process requires no resolving agent. 
• Diastereomeric crystallization – resolving agent binds to enantiomers to form a 
diastereomeric salt pair.  These salts are separated as a function of their phase 
behavior. 
• Catalytic kinetic resolution – resolving agent reacts at different rates with each 
enantiomer. (31) 
 
 Diastereomeric crystallization has dominated as the technique of choice among industrial 
pharmaceutical companies for the resolution of ibuprofen enantiomers. (31,32,33,34)  A common 
resolving agent used for the enantiomeric separation of ibuprofen is L-lysine.  It has been found 
that upon salt formation, the D-ibuprofen-L-lysinate salt exhibits about two thirds of the solubility 
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 of the L-ibuprofen-L-lysinate salt. (31)  This indicates that a decent separation of the L-ibuprofen-
L-lysinate from the D-ibuprofen-L-lysinate salt may be readily achieved.  The formation of an 
optically active salt is also ideally desirable, since the salt is more soluble in a water medium than 
the corresponding free acid of ibuprofen. (32)  Pharmacological studies have proven that the amino 
acid salt of ibuprofen exhibits increased adsorption in the blood stream as compared to the free 
acid. (35)  Thus, an effective, inexpensive, and pharmacologically valuable product is produced by 
this technique. 
 
 
 
 
2.5  Supercritical Fluids 
 
 
 
 Though researchers have studied supercritical fluids for more than one hundred years, the 
realization of its solvent potential and utilization has been evident only for the last two decades. 
(36)  A fluid is considered supercritical when the temperature and pressure combination exceed 
those of its critical point.  These media possess unique properties, which make them attractive for 
many chemical processes. The prominent feature of a supercritical fluid is the ability to adjust the 
solvent strength by varying the density.  This may be accomplished without changing the bulk 
composition or reaction temperature. (38)  In addition to its variable solvent strength, other 
properties add to its attractiveness as a chemical solvent.  It exhibits liquid like densities, while 
maintaining gas like diffusivities and viscosities.  Low surface tension allows SCF’s to penetrate 
into microporous or geometrically complex matrices. (36)  Solvent removal may be accomplished 
by simply reducing the pressure, thereby creating a clean and safe alternative to traditional solvent 
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 mediums. Currently, these fluids are used commercially in such processes as coffee 
decaffeination, edible oils extraction, isomer separation, and in the treatment of waste streams. (38) 
 The most commonly used supercritical fluid is carbon dioxide.  Supercritical CO2 
possesses reasonable critical properties (Tc= 31.1°C and Pc= 72.8 atm), chemical inertness, and 
low toxicity. (39)  The dielectric constant, which is a description of its  “tunable” solvent strength 
ranges from 1.05 to 1.5 at 60°C and 50 to 500 bar, respectively.  This small range allows for fine 
tune control of pressure sensitive processes.  Supercritical CO2 also possesses induced dipole 
moments, Lewis acid properties, and quadrapole interactions.  These characteristics allow CO2 to 
solvate a number of chemical compounds with varying polarity.   
 For many compounds, these interactions are not adequate to efficiently partition the 
sample into the bulk supercritical fluid phase.  Other supercritical fluids may overcome this 
deficiency by a change of the physical properties in the bulk medium, such as fluoroform or sulfur 
hexafluoride, but reasonable critical properties, cost, and environmental concerns, such as the 
greenhouse effect and ozone layer degradation, may limit their use. (38)  The physical properties of 
some supercritical fluids are shown in Table 3.  
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 Table 3  Critical Temperatures and Pressures for Supercritical Fluids (36) 
 
 
SOLVENTS CRITICAL TEMPERATURE 
(OC) 
CRITICAL PRESSURE 
(BAR) 
Water 374.2 220.5 
Carbon Dioxide 
Ethane 
Ethylene 
Propane 
Propylene 
Cyclohexane 
Isopropanol 
Benzene 
Toluene 
p – Xylene 
Chlorotrifluoromethane 
Trichlorofluoromethane 
Ammonia 
31.1 
32.2 
9.3 
96.7 
91.9 
280.3 
235.2 
289.0 
318.6 
343.1 
28.9 
198.1 
132.5 
73.8 
48.8 
50.4 
42.5 
46.2 
40.7 
47.6 
48.9 
41.1 
35.2 
39.2 
44.1 
112.8 
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 3.0 RESEARCH OBJECTIVES 
 
 
 
Direct resolution of ibuprofen enantiomers as a function of their diastereomeric derivatives is 
a common method that is employed in both chromatographic and crystallization methods.  
Diastereomeric crystallization is classified as a “low technology” approach due to its simplicity, 
yet more than 65% of market drugs are resolved by this method. (4)  The advantage of using a 
resolving agent in solution is the short reaction times based upon the bonding characteristic of 
the resultant complexes such as diastereomeric ion pairing, hydrogen bonding, or hydrogen ion 
pairing. (30)  In addition, the original compounds, namely the resolving agent and the free acid of 
ibuprofen, may be recovered through simple cracking techniques.     
Our goal is to develop a separation system, which enables us to resolve the enantiomers of 
ibuprofen in the form of their diastereomeric salts.  This process will be designed to operate in a 
thermodynamic resolution mode, which is a proven technology in organic solution and thus, 
potentially transferable to carbon dioxide.  Racemic ibuprofen is soluble in CO2 at 40 oC as 
shown from experimental phase behavior measurements, which were consistent with the results 
of Khundker and coworkers. (29)  The solubility of ibuprofen alone in carbon dioxide indicates 
that a feasible separation process may be designed. 
 Fogassy and Simandi have attempted to resolve the enantiomers of ibuprofen as 
diastereomeric salts in carbon dioxide.  They formed ibuprofenate salts in organic media such as 
chloroform prior to loading a high pressure reactor.  The unreacted free ibuprofen was then 
extracted with carbon dioxide, assuming that the ibuprofenate salts were insoluble.  
Enantiomeric excesses up to 42% were achieved. (43)  The limitation to this process is based not 
only on the selectivity of the chiral amine used for salt formation, but also the solvent in which 
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 salt formation took place.  The investigators were not taking advantage of the solubility 
difference between the diastereomeric salt pair.  Instead they are relying on the selectivity of an 
organic chiral amine, which in general does not possess the magnitude of selectivity of 
something like an enzyme.  In addition, this selectivity may change as a function of solvent 
characteristic. 
 Specifically, we would like to propose a somewhat different approach than that of 
Fogassy et al., namely the development of a carbon dioxide soluble chiral resolving agent for 
diastereomeric extraction of the desired enantiomers.  As opposed to Fogassy who prepared 
their diastereomeric salts in organic solution previous to CO2 extraction, our separation scheme 
involves a combination of in situ salt formation and extraction.  This will be accomplished by 
creating custom designed, CO2 soluble resolving agents which will bind specifically to the 
enantiomers of ibuprofen.  Any observed differences in solubility between the salt pair will be 
maximized as a function of the operating pressure, thus, taking advantage of the variable solvent 
strength of the supercritical carbon dioxide medium.  
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 4.0  MOLECULAR DESIGN OF A CHIRAL RESOLVING AGENT FOR THE 
ENANTIOMERIC RESOLUTION OF RACEMIC IBUPROFEN 
 
 
 
 
4.1  Introduction 
 
 
 
The application of computer based simulation models to describe the physical properties 
of chemical compounds has become a powerful tool in the fields of biochemistry, organic 
chemistry, and chemical engineering.  These computer models utilize a force field, which 
contains a set of analytical potential energy functions operating within the realm of classical 
mechanics.  These force fields are used to calculate molecular energy minimizations and 
dynamics to provide information relating to structural, physical, and electrical properties of a 
particular compound. 
 There exists many common force fields with which to perform these calculations, such as 
Allinger’s MM2, Allinger’s modified MM3, Amber and CHARM, and OPLS. (44,45,46,47)  The 
principle function of each force field is to mathematically describe and translate a multitude of 
physical phenomena such as intrinsic strain of organic molecules, structure and dynamics of 
simple liquids and solids, thermodynamics of protein binding, receptor ligand interactions, and 
transitional conformations into understandable, representative pictures of chemical processes. 
(44)  Due to an increased understanding of the complexities of these chemical and biological 
processes, the number of modified and new force fields have been increasing in the past ten 
years to effectively incorporate uncommon geometry and polar properties. (45)  In addition, 
many of these computational methods have been modified for use in supercritical fluid 
technology, especially in extraction applications. (48,49,50)  
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 4.2  Design Rational 
 
 
 
4.2.1  Selection of a Resolving Agent and CO2 Philic Tail 
 
 
 
The primary drawback to using supercritical carbon dioxide as a process media for 
enantiomeric separation is its poor ability to solubilize most polar compounds in at moderate 
pressures.  Fortunately, racemic ibuprofen is soluble in carbon dioxide, which has also been 
confirmed by Khunder, et.al. (29)  The challenge, then, is to develop appropriate, highly CO2 
soluble (or “CO2 philic”) resolving agents that not only exhibit good CO2 solubility, but also 
maintain selectivity similar to that of its native (CO2 phobic) state, taking into consideration 
variable solvent effects.  The first step in this process is to identify chiral bases that have been 
used successfully in ion pairing separation schemes for racemic acids.  A listing of these agents 
and their potential carbon dioxide solubility is shown in Table 4.  
Two important chemical criteria must be applied to potential agents in order to render 
them suitable for enantiomeric resolution in a carbon dioxide environment.  First, the reaction 
conditions used during the derivatization process must be mild enough so as not to induce 
inversion of the chiral center, thus altering the agent’s natural selectivity.  The second criteria 
focuses on the structure of the natural agent itself.  Though there does not exist a well defined set 
of rules for enantioselectivity of an ion pairing agent, empirical evidence suggests that functional 
groups, particularly those that possess hydrogen bonding potential, located close to the chiral 
center are important in defining a rigid, steric environment for selectivity to be determined. (30)  
Modification of those groups may result in a loss of the agent’s natural selectivity.  Thus, a 
resolving agent should be derivatized at a functional group far removed from the chiral center.  
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 From the list of potential candidates in Table 4, L-lysine and quinine were chosen based on the 
previous requirements for chemical modification.  The native chemical structures of these two 
resolving agents are shown below in Figure 3. 
 
 
Table 4  Chiral Bases Utilized in the Resolution of Racemic Acids (51,52)  
 
 
CHIRAL BASE CO2 SOLUBILITY 
L-lysine         * Negligible 
Aspartame         * Negligible 
Cinhonine         * Negligible 
Quinine         ** Partial 
α−Methylbenzylamine         ** Partial 
α−Methyl DOPA         ** Partial 
Troger’s Base         * Negligible 
1R, 2S-Ephedrine         ** Partial 
S-(+)-Phenylglycinol         ** Partial 
S(-)-2-Amino-3-phenyl-1-propanol         ** Partial 
*  Negligible = 10-8 mole fraction at 2000 bar 
 **  Partial = estimated as less than 20 weight % soluble at 35 oC and 7000 psi 
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Figure 3  Native Structures of L-Lysine and Quinine 
 
 
 
 CO2 philic ligands may be classified into three primary groups, based upon their 
chemical compositions as shown in Table 5.  For our experimental purposes we have chosen to 
derivatize our agents with fluoroalkyl, fluoroether, and silicone tails.  These materials are readily 
available and relatively easy synthetic preparations are known.  The chemical structures of the 
proposed CO2 philic agents are shown below in Figures 4a thru 4c. 
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Figure 4a  L-Lysine Fluoroalkyl Analogs 
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Figure 4b  L-Lysine Hexafluoropropylene Oxide Analogs  
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Figure 4b  L-Lysine Hexafluoropropylene Oxide Analogs Cont. 
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Figure 4c  Quinine Fluoroalkyl and Silicone Analogs 
 
 
 
Table 5  Liquid and Supercritical CO2 Philic Functional Groups 
 
 
FUNCTIONAL GROUP REASON 
Tertiary amines, aliphatic esters and ethers • Lewis Base 
Fluoroalkyl and fluoroethers • Low solubility parameter 
• Low cohesive energy 
density 
Silicones • Low solubility parameter 
 
 
 
4.2.2  Calculation Design 
 
 
 
Several resolving agent candidates were screened for ibuprofen using computational 
chemistry.  Predicting the selectivity of a chiral resolving agent was estimated using a molecular 
mechanics package to evaluate the lowest energy conformations of the diastereomeric salt pairs 
composed of ibuprofen and a particular resolving agent.  Molecular mechanics is an empirically 
based calculational design whose fundamental, physical premise is that all bond lengths between 
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 atoms have a natural length and angle which defines the minimum energy of the molecule. (53)  
Theoretical, structural differences between these molecules suggests differences in physical 
properties which can then be tested experimentally. 
 The total energy of a molecular conformation compared to that of a hypothetical strain-
free molecule of the same constitution is termed the steric energy. (54)  Steric energy is the 
parameter which will be used to evaluate the selectivity of a resolving agent.  The differences in 
steric energy between the ibuprofenate diastereomeric salts gives an indication of how 
structurally different the two molecules are.  The greater the difference in steric energy between 
the salt pairs, the greater the three dimensional structural dissimilarity, and, thus, variances in 
their physical properties.   
 A minimum difference of 3 kcal/mol for any diastereomeric pair was required for a 
resolving agent to be classified as selective.  This standard is derived from the relationship 
between stability and isomeric composition at equilibrium, which may be simply expressed in 
terms of the equilibrium constant Keq as shown below; 
 
 
 
Keq = exp( -∆E/RT)              (4-1)
  
 
 
where ∆E represents the energy difference between the two isomers, T is the absolute 
temperature in Kelvin, and R the gas constant.  Table 6 lists the ∆E required to obtain specific 
enantiomeric compositions.  From Table 6 an energy difference of 3 kcal/mol would yield an 
enantiomeric excess greater than 99%. (54) 
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 Table 6  Theoretical Enantiomeric Compositions 
 
 
MORE STABLE 
ISOMER (%) 
LESS STABLE 
ISOMER (%) 
ENERGY DIFFERENCE 
∆E (KCAL/MOL) 
50 50 0 
75 25 0.651 
90 10 1.302 
95 5 1.744 
99 1 2.722 
99.9 0.1 4.092 
 
 
 
 
4.3  Experimental 
 
 
 
  The relative steric energy difference between the minimized conformations of the 
various salts with modified and unmodified resolving agents as reported in Tables 7a – 7d was 
calculated.  The specific interactions between the resolving agents and ibuprofen were based 
upon relevant crystallographic data. (55,56,57,58,59,60)  The models were created in the editor 
program of the CAChe molecular modeling software.  From the general structure, a mechanics 
calculation based on Allinger’s MM2 force field was performed in order to obtain local 
minimized structures.  To confirm that a minimized structure had been determined from the 
mechanics calculation, a dynamics calculation was run in order to verify the global energy 
minimum conformation.  In this computation the molecule is theoretically heated from 0 to 600 
Kelvin.  A trajectory plot of potential energy versus time is found.  From this plot, ten random 
structures were chosen and their conformations re-minimized.  The difference in the steric 
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 energy values for the ten random structures was an indication of the stability and energy 
minimum of the final conformation. 
 
 
 
 
4.4  Results and Discussion 
 
 
 
Molecular mechanics was used as a measure for conformational analysis and not as a 
predictor of solubility or phase behavior in a CO2 solution.  The modeling employed here 
simulates a single molecule in vacuo, and thus the molecule is not a solid state structure and does 
not include packing forces.  Weak bonds may exists in the solid state, such as ionic or hydrogen 
bonds, that may or may not exist in solution.  These types of bonds are more likely to exist in 
media of low polarity such as hydrocarbons and carbon dioxide, and less likely in media of 
higher polarity such as water or other protic solvents. (61)  Since the proposed processing medium 
is supercritical carbon dioxide, which exhibits a Hildebrand solubility parameter similar to 
perfluoro hexane, it is assumed that those weak bonds formed from the chiral complex are stable 
within this fluid.   
 
 
 
4.4.1  Effect of a Fluoroalkyl Tail on the Selectivity of L-Lysine 
 
 
 
 As shown in Table 7a, free L-lysine exhibits a high selectivity towards the enantiomers of 
ibuprofen when binding occurs at the ε amine.  Preferential complexation at that basic site is 
again verified by experimental crystallographic data. (55,56,57,58,59,60)  This amino acid is currently 
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 the resolving agent of choice for resolution of racemic ibuprofen by crystallization techniques 
which employ chiral resolving agents. (31)  Upon chemical modification with an eight carbon, 
fluoroalkyl tail, the selectivity of the amino acid is predicted to decrease.  Functionalization at 
the α amine produced a molecule which exhibits a slight decrease in selectivity.  Since the 
ε amine functions as the site at which ion pairing occurs, a slight predicted decrease in the 
selectivity of the agent is reasonable.  It can be proposed that the tail itself is the limiting factor.  
The ε amine is located far enough away from the tail in structure 2 so as not to be effected by the 
electron withdrawing effect of the fluorinated chain.  The physical presence of the tail itself may 
be interfering in the formation of the rigid environment required for chiral discrimination. 
A significant reduction in the selectivity of the agent derivatized at the ε amine (structure 
3, Table 7a) is observed as compared to its corresponding modified structure where the fluoro 
tail is placed at the α amine (structure 2, Table 7a).  In this instance the same additional 
hydrogen bonding capability is provided by the presence of an amide located at the tail section.  
The difference, then, is the complexation at the α and ε amines.  As shown in structure 1, the ε 
amine is the favored site.  Therefore, it is expected that complexation at the α amine is 
disfavored, and this result is consistent with the results obtained for the native molecule 
(structure 1).  The fluoroalkyl tail, then, does not significantly appear to effect chiral 
discrimination. 
 The last agent in Table 7a was created in order to observe the effect of leaving both 
primary amines free for ion pairing with ibuprofen’s carboxy group.  In addition, a two carbon 
spacer was added between the native amino acid and the fluoroalkyl tail, in order to shield the α 
amine from the highly electron withdrawing effect of the fluorinated tail.  The effect of this 
structural configuration is interesting, in that the selectivity at the α amine binding site is 
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 predicted to increase as compared to its binding at the α amine of the native molecule(structure 1 
in Table 7a).  The additional, potential hydrogen bonding capability contributed by the amide 
group located in close proximity to the α amine may possibly contribute to the stabilization of 
the chiral complex.  A significant decrease in chiral discrimination is observed with 
complexation occurring at the ε amine.  Due to the length of the tail and its flexibility about its 
single bonds, the ability of ibuprofen, a relatively bulky substrate, to preferentially bind at the ε 
amine may be substantially minimized. 
 
 
 
4.4.2 Effect of Krytox Perfluoropolyether Based Tail on the Selectivity of L-Lysine 
 
 
 
 The results for L-lysine modified with a perfluoropolyether tail are shown in Table 7b.  
Here, we have used the structure for a Dupont product (Krytox functional fluids), which is an 
oligomer of hexafluoropropylene oxide.  Although Krytox fluids are available in several 
molecular weights, we have confined our modeling work to that with an average molecular 
weight of 2500.  This particular material was chosen due to its previous use in our laboratories as 
a CO2 soluble modifying agent. (62,63,64,65,66)  For the agents shown as structures 1 and 2 in Table 
7b, the selectivity as compared to the native agent was significantly reduced.  The difference in 
steric energies of the diastereomeric salt pairs is minimal, which renders the agent non-selective 
according to the criteria that a difference of 3 kcal/mol or greater is required for agent selectivity.  
It can be hypothesized that the tail is an extremely flexible entity, which possesses the ability to 
twist and wrap itself around the binding pocket, excluding the space usually available for the 
ibuprofen molecule.  Therefore, there is not a real difference in selectivity between the structures 
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 1 and 2 in Table 7b as compared to the two same molecules, structures 2 and 3 in Table 7a, 
which possess the fluoroalkyl CO2 philic tail.   
 Interestingly, structure 3 in Table 7b showed relatively high selectivity as compared to its 
fluoroalkyl modified counterpart.  These results are suspect due to the inability of the force field 
employed to run a completed dynamics calculation.  The values reported for that particular 
compound were determined from only the mechanics calculations.  The value and the 
corresponding structure obtained from that calculation represent most likely a local minimum 
and not the lowest energy structure available for that molecule.   
 
 
 
4.4.3 Effect of Lancaster Perfluoropolyether Based Tail on the Selectivity   
           of L-Lysine 
 
 
 
 Because functional oligomers of hexafluoropropylene oxide at short chain lengths (3-5 
repeat units) from Lancaster Chemical Co. can be obtained, such structures were included in the 
modeling study.  The results for L-lysine modified with the 3 repeat unit perfluoroether tails are 
shown in Table 7c.  The short perfluoroether tail, or more specifically perfluoro-2,5,8-trimethyl-
3,6,9-trioxadodecanoyl, as modeled in these calculations, possesses a molecular weight of 664 
g/mol.  This particular material is a recent addition to the perfluoroether family of compounds, 
which has been shown in our laboratories to impart good CO2 solubility. (67)   
 As shown in Table 7c, the selectivity of these modified agents as compared to the native 
agent are all predicted to be significantly reduced, regardless of the placement of the 
perfluoroether tail.  The same trends as those observed in the previous two cases are followed.  
Tail modification at the α amine results in higher predicted selectivity as compared to tail 
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 placement at the ε amine.  Placement of the tail so as to maintain both the α amine and the ε 
amine free for ion pairing exhibits a higher predicted selectivity at the α amine binding site than 
at the ε amine binding site.  According to the selectivity criteria set forth in the previous section, 
none of the agents in Table 7c qualify for use in the resolution of racemic ibuprofen. 
 
 
 
4.4.4 Effect of Tail Structure and Length on the Predicted Selectivity of the L-  
            Lysine Derivatives 
 
 
 
 Intially, the fluoroalkyl tails seem to produce agents which would impart better 
selectivity than those possessing the perfluoro polypropylene oxide tails.  The rigidity of the 
fluoroalkyl chain is greater than that of the perfluoro polypropylene oxide.  This characteristic 
may assist in maintaining the proper, well defined, rigid environment necessary for chiral 
discrimination as opposed to a chain which exhibits greater mobility.  The chain length in these 
calculations appears to have a strong influence over the selectivity of the agent, where as the tail 
length increases, the calculated selectivity decreases dramatically.  From Tables 7a, 7b, and 7c, 
the only suitable agent determined theoretically for enantiomeric separation of ibuprofen is 
shown below in Figure 5. 
 
 
 
 
 31
 CH
H
N
COOCH3
(CH2)4
NH2
C(F2C)6
O
F3C
 
 
 
Figure 5  N-(Perfluorooctanoyl)-L-Lysine Methyl Ester 
 
 
 
4.4.5  Effect of Perfluoroalkyl and Silicone Tails on Quinine Selectivity 
 
 
 
 Quinine has found extensive use as a resolving agent for racemic, chiral acids. (2)  Ion 
pairing with quinine occurs at a tertiary amine located in the bicyclic portion of the molecule, as 
opposed to a primary amine in the case of L-lysine.  This fact imparts a significant advantage in 
the use of quinine as a resolving agent for racemic ibuprofen over L-lysine in supercritical 
carbon dioxide.  Primary amines, depending upon the temperature and pressure of the operating 
system and the pKa of the amine, can form carbamates with CO2.  This reaction is not observed 
when tertiary amines are utilized in high pressure carbon dioxide systems. 
 The computed selectivity for the native quinine molecule, determined as 3.0 kcal/mol, 
meets the minimum required value.  Any chemical modification imparted to the native molecule 
will likely result in a reduction in the molecular selectivity as shown in Table 7d.  Derivatization 
with a fluoroalkyl tail at the secondary alcohol group to create an ester functionality results in a 
67% decrease in ∆∆E.  Here, the placement of the tail interferes with the binding of the 
ibuprofen molecule, not only through steric hindrance, but also by elimination of a primary 
hydrogen binding site at the asymmetric carbon.  
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  In an effort to maintain the natural selectivity of the native molecule, another functional 
group located on the quinine molecule was sought for modification, and thus the vinyl group 
located far from the chiral center was considered.  A silicone based tail was chosen, which can 
be easily accomplished synthetically via hydrosilation over a platinum catalyst. The 
computational results indicate reasonable preservation of the selectivity of the quinine molecule, 
most likely due to the preservation of an unrestricted binding pocket (structure 3 in Table 7d). 
 The last molecule under consideration, structure 4 in Table 7d, is the chiral inverse of 
quinine, namely quinidine.  Interesting, this molecule does not exhibit the same degree of 
selectivity as quinine, possibly due to the geometrical configuration of the binding pocket.  If the 
chiral secondary alcohol was not a vital component in the formation of the chiral complex, then 
each configuration, -(-) or –(+) (structures 1 and 4), would likely exhibit similar selectivity.  This 
effect is not observed for structures 1 and 4.  Thus, the secondary alcohol appears to be a 
necessary component in complex formation.  This theory is reinforced by examining the 
fluoroalkyl derivatized agent of quinine, which displays a markedly reduced selectivity due to 
elimination of the hydrogen bonding potential of the secondary alcohol. 
 Of the potential agents for enantiomeric resolution from Table 7d, the silicone modified 
quinine agent exhibits the greatest potential for resolution of racemic ibuprofen.  The structure of 
this molecule is shown below in Figure 6. 
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Figure 6  Silicone Functionalized Quinine 
 
 
 
 
4.5  Concluding Remarks 
 
 
 
These results highlight the first step towards the development of a custom designed, 
selective chiral resolving agent for use in the enantiomeric resolution of racemic ibuprofen in 
supercritical carbon dioxide.  The force field employed, Allinger's MM2 has found sufficient use 
for the molecular geometries and energies of the complexes that were modeled in this study.  
This force field is well suited for small molecular systems which do not contain hybridization 
greater than sp3 or metal ions.  The major limitation in using Allinger's MM2 is the 
underestimation of hydrogen bonding by a factor of approximately three.  Though the hydrogen 
bond is the primary bond between the components of the chiral complex, no substantial error 
results because it is the difference in steric energy rather than the absolute values which are of 
interest.  This underestimation is assumed to be spread equally throughout the two 
diastereomeric salt pairs.  Though these chiral complexes were modeled in vacuo, they give an 
indication of agents which are more likely to give good separation results even in supercritical 
carbon dioxide.   
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 Table 7a  L-Lysine Derivatized with Perfluoroalkyl Based Tail 
 
 
 
Resolving 
 Agent 
 
∆ ∆ E (Kcal/mol) 
Ibuprofenate 
Complexes 
 
Theoretical % 
Enantiomeric 
Excess 
 
1.    
CH
H2N COOH
(CH2)4
NH2  
 
4.86 
* binding at e amine 
 
0.61 
* binding at a amine 
 
99.9 
 
 
64.4 
 
 
2.    
CH
H
N
COOCH3
(CH2)4
NH2
C(F2C)6
O
F3C
 
 
 
 
3.82 
 
 
99.8 
 
3.   
CH
H2N COOH
(CH2)4
NH C
O
(CF2)6 CF3
 
 
 
 
0.56 
 
 
 
61.2 
 
CH
H2N C
(CH2)4
NH2
H
N
O
(CH2)2
H
N C
O
(CF2)6 CF3
 
4. 
 
0.62 
* binding at e amine 
 
2.35 
* binding at a amine 
 
65.0 
 
 
98.1 
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 Table 7b  L-Lysine Derivatized with Poly Hexafluoropropylene Oxide Based Tail 
 
 
 
Resolving 
 Agent 
 
∆ ∆ E 
(Kcal/mol) 
Ibuprofenate 
Complexes 
 
Theoretical 
% 
Enantiomeric 
Excess 
 
1.     
CH
H2N COOH
(CH2)4
NH C
O
C
F
CF3
OCF2CF F
14
CF3
 
 
 
1.86 
 
 
95.7 
 
2.     
CH
H
N
COOCH3
(CH2)4
NH2
CC
O
CF3
F
CFCF2OF
14
F3C
 
 
 
1.22 
 
 
87.3 
CH
H2N C
(CH2)4
NH2
NH
O
(CH2)2 NH C
O
C
F
CF3
OCF2CF F
14
CF3
 
3. 
 
* NC 
 
 
* NC 
 
N/A 
 
 
N/A 
 
* NC = No Convergence 
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 Table 7c  L-Lysine Derivatized with Perfluoroether Based Tail 
 
 
 
Resolving 
 Agent 
 
∆ ∆ E 
(Kcal/mol) 
Ibuprofenate 
Complexes 
 
Theoretical % 
Enantiomeric 
Excess 
 
1.
CH
H2N COOH
(CH2)4
NH C
O
C
F
CF3
OCF2CF O(CF2)2CF3
2
CF3
 
 
 
0.69 
 
 
68.9 
 
2.
CH
H
N
COOCH3
(CH2)4
NH2
CC
O
CF3
F
CFCF2OCF3(CF2)2O
2
F3C
 
 
 
 
0.44 
 
 
52.5 
 
*  This structure can be seen below the Table in the 
footnote. 
 
 
1.34  
* binding at e 
amine 
 
1.78 
* binding at a 
amine 
 
89.6 
 
 
95.0 
 
*  Structure was too large for cell area allocated. 
 
CH
H2N C
(CH2)4
NH2
NH
O
(CH2)2 NH C
O
C
F
CF3
OCF2CF O(CF2)2CF3
2
CF3
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 Table 7d  Quinine Derivatized with Perfluoroalkyl and Silicone Based Tails 
 
 
 
Resolving 
 Agent 
 
∆ ∆ E (Kcal/mol) 
Ibuprofenate 
Complexes 
 
Theoretical % 
Enantiomeric 
Excess 
 
1.     N
CH3O
HO N
 
 
 
3.0 
 
 
99.3 
 
2.     N
CH3O
O N
C
O
(CF2)6CF3
 
 
 
 
1.07 
 
 
 
81.2 
 
 
3. N
CH3O
HO N
SiOSiOSiCH3
CH3
CH3 CH3
CH3
CH3
CH3
 
 
 
 
 
2.65 
 
 
 
 
98.8 
 
4.     N
CH3O
HO N
 
 
 
1.22 
 
 
87.3 
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 5.0  SYNTHETIC PROCEDURES FOR CUSTOM DESIGNED, CO2 SOLUBLE 
RESOLVING AGENTS 
 
 
 
Materials 
The following is a list of reagents used as received, if not otherwise specified.   
 
• Anhydrous tetrahydrofuran, anhydrous pentane, A.C.S. grade chloroform, A.C.S. grade n-
hexane, A.S.C. grade methyl alcohol, 1,1,3-trifluorotrichloroethane, perfluoro 1,3-
dimethylcyclohexane, A.C.S. grade dimethyl formamide, anhydrous toluene, triethylamine, 
pentadecafluorooctanoyl chloride, thionyl chloride, and palladium hydroxide 20 wt% Pd (dry 
basis) on carbon from Aldrich Chemical Company.   
 
• Nε-CBZ-L-lysine methyl ester hydrochloride, Nα-CBZ-L-lysine, Nα,Nε-di-CBZ-L-lysine 
N-hydroxysuccinimide ester, quinine, and quinidine from Sigma Chemical Company 
 
• Poly (hexafluoropropylene oxide) carboxylic acid terminated (MW = 2500) from Dupont 
 
• Perfluoro 2,5,8-trimethyl-3,6,9-trioxadodecanoyl fluoride from Lancaster Synthesis 
 
• 1,1,1,3,3,5,5-heptamethyltrisiloxane and platinum divinyl tetramethyl disiloxane complex in 
xylene from Gelest 
• Ethylene diamine from Fisher 
 
• Nitrogen, argon, and hydrogen gases (high purity grade) from Liquid Carbonic 
 39
  
All products were characterized by 1H NMR.  Table 8 lists the structural characterization for 
each product. 
 
Preparation of N-(Perfluorooctanoyl)-L-Lysine Methyl Ester 
 
CHH2N COOCH3
(CH2)4
NHCBZ . HCl
+
THF / N(CH2CH3)3
C Cl
O
(F2C)6F3C
CHHN COOCH3
(CH2)4
NHCBZ
C
O
(F2C)6F3C
2  (CH3CH2)3NH
+Cl-
+
where CBZ =
O
O
 
 
 
Figure 7  Reaction Scheme 1 
 
 
 
 Typically, 15 mmols (5.00 g) of Nε-CBZ-L-lysine methyl ester hydrochloride, 30 mmols 
(4.21 ml) of triethylamine, and 50 ml of anhydrous tetrahydrofuran were charged to a 250 ml, 
three neck flask which had been previously flushed with nitrogen.  Subsequently, 15 mmols 
(3.75 ml) of pentadecafluorooctanoyl chloride in 10 ml of anhydrous tetrahydrofuran, was added 
dropwise with vigorous stirring over a 10 minute time period under nitrogen.  After 10 minutes, 
the mixture was vacuum filtered and the filtrate then concentrated under vacuum.  The white 
solid was then recrystallized from a 1:1 tetrahydrofuran/pentane solution.  (Yield = 91.8%).   
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CH
HN
COOCH3
(CH2)4
NHCBZ
C
O
(F2C)6F3C 20% PdOH/C
CH3OH
CH
HN
COOCH3
(CH2)4
NH2
C
O
(F2C)6F3C
+
+ CO2
 
 
 
Figure 8  Reaction Scheme 2 
 
 
 
 To cleave the CBZ protecting group, a one arm flask was charged with 5 wt% of the 
palladium hydroxide on carbon catalyst in 5 ml of methyl alcohol.  The flask was then evacuated 
and charged with hydrogen at 1 atm, and the mixture of 20 % palladium hydroxide on carbon 
catalyst, hydrogen, and methyl alcohol stirred for 10 minutes.  The product from Reaction 
Scheme 1, 3.98 mmols (2.20 g), is dissolved in 10 ml of methyl alcohol and added to the flask.  
The flask is again evacuated, and the mixture is placed under a hydrogen blanket and stirred.  
After 4 hours, the catalyst is separated from the solution by filtration and the methyl alcohol 
removed under vacuum.  The white solid was redissolved in tetrahydrofuran and recrystallized 
from a 1:1 mixture of tetrahydrofuran/pentane.  (Yield = 53.0 %).   
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 Preparation of N'- (Perfluorooctanoyl)-L-Lysine  
 
 
CH
H
N COOH
(CH2)4
NH2
CBZ
+ C Cl
O
(F2C)6F3C CH
H
N COOH
(CH2)4
NH
CBZ
C(F2C)6F3C
O
(CH3CH2)3NH
+Cl-
+
THF / N(CH2CH3)3
 
 
 
Figure 9  Reaction Scheme 3 
 
 
 
The same synthetic procedure was followed as in Reaction Scheme 1.  Typically, 10.7 mmols 
(3.00 g) of Nα-CBZ-L-lysine, 10.7 mmols (1.49 ml) of triethylamine, and 40 ml of anhydrous 
tetrahydrofuran were charged to a 250 ml, three neck flask.  Subsequently, 10.7 mmols (2.65 ml) 
of pentadecafluorooctanoyl chloride in 10 ml of anhydrous tetrahydrofuran was added dropwise.  
The red solid was recrystallized from 1:1 chloroform/n-hexane solution.  (Yield = 16.6 %) 
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 CH
H
N COOH
(CH2)4
NH
CBZ
C(F2C)6F3C
O
20% PdOH/C
CH3OH
CHH2N COOH
(CH2)4
NHC(F2C)6F3C
O
+ + CO2
 
 
 
Figure 10  Reaction Scheme 4 
 
 
 
The same synthetic procedure for CBZ deprotection was followed as in Reaction Scheme 2.  
Typically, the product from Reaction Scheme 3, 1.77 mmols (1.2 g), 0.065 g 20 % PdOH on 
carbon, and 15ml of methyl alcohol were added to a one arm flask.  The product was a light red 
solid.  (Yield = 35.2%) 
 
 
Preparation of Perfluorooctanoyl L-Lysine with Alkyl Spacer 
 
 
CH
H
N C
(CH2)4
NH
CBZ
CBZ
O
O N
O
O
+  NH2(CH2)2NH2
THF
CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2 NH2
HN CBZ
HO N
O
O+
 
 
 
Figure 11  Reaction Scheme 5 
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CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2 NH2
HN CBZ
THF / N(CH2CH3)3
+ C Cl
O
(F2C)6F3C (CH3CH2)3NH
+Cl-
+
CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2
H
N
HN CBZ
C
O
(CF2)6 CF3
 
 
 
Figure 12  Reaction Scheme 6 
 
 
 
Typically, 4.1 mmols (0.27 ml) of ethylenediamine in 10 ml of anhydrous tetrahydrofuran were 
charged to a 250 ml, three neck flask which had been previously flushed with argon.  
Subsequently, 4.1 mmols (2.09 g) of Nα,Nε-di-CBZ-L-lysine-N-hydroxysuccinimde ester in 50 
ml of anhydrous tetrahydrofuran was added dropwise with vigorous stirring.  After 20 minutes, a 
white precipitate formed.  The reaction mixture was further diluted with 50 ml of anhydrous 
tetrahydrofuran and stirred vigourously.  Then 3 mmols (0.74 ml) of pentadecafluorooctanoyl 
chloride in 10 ml of anhydrous tetrahydrofuran was added dropwise with vigorous stirring under 
argon.  After 10 minutes, the mixture was vacuum filtered and the filtrate then concentrated.  The 
white solid was then recrystallized from a 1:1 tetrahydrofuran/pentane solution.  (Yield =  
56.7%).   
 
 
 
 
 44
 CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2
H
N
HN CBZ
C
O
(CF2)6 CF3
20% PdOH/C
CH3OH
+ 2  CO2
+
CHH2N C
(CH2)4
O
H
N (CH2)2
H
N
NH2
C
O
(CF2)6 CF3
2
 
 
 
Figure 13  Reaction Scheme 7 
 
 
 
The same reaction protocol was followed for CBZ deprotection of an amine as described in 
Reaction Scheme 2.  Typically, the product from Reaction Scheme 6, 2.29 mmols (2.0 g), 0.105 
g 20% PdOH on carbon, and 15 ml of methyl alcohol were added to a one arm flask.  The 
product was a yellow solid.  (Yield = 39.2 %) 
 
Preparation of N-(Polyperfluoroether)-L-Lysine Methyl Ester 
Poly Hexafluoropropylene Oxide 
 
To improve the “CO2 philicity” of the functionalized lysine, analogues were prepared using an 
oligomer of hexafluoropropylene oxide (Trade name is Krytox, MW = 2500) capped with a 
carboxylic acid group.  In order to increase its reactivity, the carboxylic group is converted to an 
acid chloride.  In a typical experiment, 60 mmols (150 g) of poly (perfluoropropylene oxide), 50 
ml of perfluoro -1,3-dimethylcyclohexane, 120 mmols (8.7 ml) of thionyl chloride, and 60 
mmols N,N-dimethyl formamide (4.66 ml) were charged to a three neck flask, which was 
previously flushed with nitrogen.  The reaction was heated under a nitrogen blanket to 76 oC, and 
the mixture was refluxed for 6 hours with vigorous stirring.  The phases were then separated and 
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 the solvent removed under vacuum.  Conversion from the carboxylic acid to the acid chloride 
was characterized by FT-IR (disappearance of the acid peak at 1776 cm-1 and appearance of the 
acid chloride peak at 1807 cm-1). 
 
 
 
 
CHH2N COOCH3
(CH2)4
NHCBZ . HCl
Poly DMAP
CC
O
CF3
F
CFCF2OF
14
F3C
Cl+
CH
H
N COOCH3
(CH2)4
NHCBZ
CC
O
CF3
F
CFCF2OF
14
F3C
Poly DMAPH+Cl-
+
2
Cl2FCCF2Cl
 
 
 
Figure 14  Reaction Scheme 8 
 
 
 
Typically, 15 mmols (5.00 g) of Nε-CBZ-L-lysine methyl ester hydrochloride, approximately 2 g 
of Poly DMAP (crosslinked polymer of styrene and pryidine units), and 50 ml of 1,1,3-
trichlorotrifluoroethane were charged to a 250 ml, three neck flask which had been previously 
flushed with nitrogen.  Subsequently, 12.5 mmols (31.3 g) of poly hexafluoropropylene oxide 
(PHFPO) in 90 ml of 1,1,3-trichlorotrifluoroethane was added dropwise with vigorous stirring 
over a 2 hour time period under nitrogen.  After 6 hours, the mixture is vacuum filtered and the 
filtrate then concentrated under vacuum.  The product is washed with acetone, leaving a light 
yellow colored, viscous oil  (Yield = 56.0 %). 
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 CH
H
N COOCH3
(CH2)4
NHCBZ
CC
O
CF3
F
CFCF2OF
14
F3C
20% PdOH/C
CH
H
N COOCH3
(CH2)4
NH2
CC
O
CF3
F
CFCF2OF
14
F3C
+ CO2
+
C6F10(CF3)2
 
 
 
Figure 15  Reaction Scheme 9 
 
 
 
The same reaction protocol was followed for CBZ deprotection of an amine as described in 
Reaction Scheme 2 with a change in solvent.  Typically, the product from Reaction Scheme 8, 
1.20 mmols (3.2 g), 0.154 g 20% PdOH on carbon, and 15 ml of perfluoro  
1,3 - dimethylcyclohexane were added to a one arm flask.  The product was a clear, viscous oil.  
(Yield = 94.8 %). 
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 Preparation of N'-(Polyperfluoroether)-L-Lysine 
Poly Hexafluoropropylene Oxide 
 
 
 
CH
H
N COOH
(CH2)4
CBZ + Poly DMAPCC
O
CF3
F
CFCF2OF
14
Cl Poly DMAPH+Cl-
+
Cl2FCCF2Cl
CH
H
N COOH
(CH2)4
HN
CBZ
C C
CF3
F
OF2CFC F
14
CF3
O
F3C
NH2
 
 
 
Figure 16  Reaction Scheme 10 
 
 
 
The same reaction procedure was used as that described in Reaction Scheme 8.  Typically, 17.8 
mmols (5.00 g) of Nα-CBZ-L-Lysine, approximately 2 g of Poly DMAP, and 50 ml of 1,1,3-
trichlorotrifluoroethane were charged to a 250 ml, three neck flask which had been previously 
flushed with nitrogen.  Subsequently, 14.8 mmols (37.0 g) of PHFPO in 100 ml of 1,1,3-
trichlorotrifluoroethane was added.  The resultant product was a light yellow colored, viscous oil  
(Yield = 48.0 %). 
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 CH
H
N COOH
(CH2)4
HN
CBZ
C C
CF3
F
OF2CFC F
14
CF3
O
20% PdOH/C + CO2
+
C6F10(CF3)2
CHH2N COOH
(CH2)4
HN C C
CF3
F
OF2CFC F
14
CF3
O  
 
 
Figure 17  Reaction Scheme 11 
 
 
 
The same reaction protocol was followed for CBZ deprotection of an amine as described in 
Reaction Scheme 2 with a change in solvent.  Typically, the product from Reaction Scheme 10, 
1.28 mmols (3.4 g), 0.169g 20% PdOH on carbon, and 15 ml of perfluoro 1,3 -
dimethylcyclohexane were added to a one arm flask.  The product was a light brown, viscous oil.  
(Yield = 93.7 %). 
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 Preparation of (Polyperfluoroether)-L-Lysine With Alkyl Spacer 
Poly Hexafluoropropylene Oxide 
 
 
 
CH
H
N C
(CH2)4
NH
CBZ
CBZ
O
O N
O
O
THF
CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2 NH2
HN CBZ
HO N
O
O+
+  NH2(CH2)2NH2
 
 
 
Figure 18  Reaction Scheme 12 
 
 
 
CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2 NH2
HN CBZ
Poly DMAP Poly DMAPH+Cl-
+
Cl2FCCF2Cl
CC
O
CF3
F
CFCF2OF
14
F3C
Cl+
CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2
H
N
HN CBZ
C C
O
CF3
F
OF2CFC F
14
CF3
 
 
 
Figure 19  Reaction Scheme 13 
 
 
 
Typically, 5.8 mmols (0.39 ml) ethylenediamine and 10 ml of anhydrous tetrahydrofuran were 
charged to a 250 ml, three neck flask which had been previously flushed with argon.  
Subsequently, 5.8 mmols (3.00 g) of Nα,Nε-di-CBZ-L-lysine-N-hydroxysuccinimde ester in 50 
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 ml of anhydrous tetrahydrofuran was added dropwise with vigorous stirring.  After 20 minutes, a 
white precipitate formed.  The reaction mixture was further diluted with 100 ml of 1,1,3-
trichlorotrifluoroethane and stirred vigorously.   Then 2.9 mmols (7.25 ml) of PHFPO in 80 ml 
of 1,1,3-trichlorotrifluoroethane was added dropwise with vigorous stirring over a 2 hour time 
period under argon.  After 6 hours, the mixture was vacuum filtered and the filtrate then 
concentrated.  The product was washed thoroughly with acetone and resulted in a clear, pale 
yellow oil.  (Yield = 62.0 %). 
 
 
 
CH
H
N C
(CH2)4
CBZ
O
H
N (CH2)2
H
N
HN CBZ
C C
O
CF3
F
OF2CFC F
14
CF3 20% PdOH/C + 2  CO2
+
C6F10(CF3)2
2
CHH2N C
(CH2)4
O
H
N (CH2)2
H
N
NH2
C C
O
CF3
F
OF2CFC F
14
CF3
 
 
 
Figure 20  Reaction Scheme 14 
 
 
 
The same reaction protocol was followed for CBZ deprotection of an amine as described in 
Reaction Scheme 2 with a change in solvent.  Typically, the product from Reaction Scheme 13, 
1.9 mmols (5.3 g), 0.268 g 20% PdOH on carbon, and 20 ml of perfluoro  
1,3 - dimethylcyclohexane were added to a one arm flask.  The product was a yellow, viscous 
oil. (Yield = 82.1 %). 
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 Preparation of N-(Polyperfluoroether)-L-Lysine Methyl Ester 
Perfluoro-2,5,8-trimethyl-3,6,9-trioxadodecanoyl fluoride 
 
 
 
CHH2N COOCH3
(CH2)4
NHCBZ . HCl
+
CH
H
N
COOCH3
(CH2)4
NH
CC
O
CF3
F
CFCF2OCF3(CF2)2O
2
F3C
CC
O
CF3
F
CFCF2OCF3(CF2)2O
2
F3C
Cl Poly DMAP Poly DMAPH+Cl-
+
2
Cl2FCCF2Cl
CBZ  
 
 
Figure 21  Reaction Scheme 15 
 
 
 
A carboxy capped oligomer of hexafluoropropylene oxide available from Lancaster Synthesis, 
perfluoro-2,5,8-trimethyl-3,6,9-trioxadodecanoyl fluoride (MW = 664), was also used as a tail to 
increase the “CO2 philicity” of the lysine head group.  
 
The same synthetic procedure is followed as in Reaction Scheme 8.  Typically, 16.8 mmols (5.56 
g) of Nε-CBZ-L-lysine methyl ester hydrochloride, approximately 2 g of Poly DMAP, and 60 ml 
of 1,1,3-trichlorotrifluoroethane were charged to a 250 ml, three neck flask which had been 
previously flushed with nitrogen.  Subsequently, 14.0 mmols (9.30g) of perfluoro-2,5,8-
trimethyl, 3,6,9-trioxadodecanoyl fluoride in 60 ml of 1,1,3-trichlorotrifluoroethane was added 
dropwise with vigorous stirring at 45 oC over a 1 hour time period under nitrogen.  After 24 
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 hours, the mixture is vacuum filtered and the filtrate then concentrated under vacuum.  The 
resultant product was a light orange colored, viscous oil  (Yield =  62.3 %). 
 
 
 
CH
H
N
COOCH3
(CH2)4
NH
CC
O
CF3
F
CFCF2OCF3(CF2)2O
2
F3C
CBZ
20% PdOH/C
CH3OH
+ CO2
+
CH
H
N
COOCH3
(CH2)4
NH2
CC
O
CF3
F
CFCF2OCF3(CF2)2O
2
F3C
 
 
 
Figure 22  Reaction Scheme 16 
 
 
 
The same reaction protocol was followed for CBZ deprotection of an amine as described in 
Reaction Scheme 2.  Typically, the product from Reaction Scheme 15, 2.6 mmols (2.5 g), 0.208 
g 20% PdOH on carbon, and 20 ml of methyl alcohol were added to a one arm flask.  The 
resultant product was a clear oil.  (Yield = 85.4 %).   
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 Preparation of N'-(Polyperfluoroether)-L-Lysine 
Perfluoro-2,5,8-trimethyl-3,6,9-trioxadodecanoyl fluoride 
 
 
 
CH
H
N COOH
(CH2)4
NH2
CBZ + CC
O
CF3
F
CFCF2OCF3(CF2)2O
2
F3C
Cl Poly DMAP Poly DMAPH+Cl-
+
Cl2FCCF2Cl
CH
H
N COOH
(CH2)4
NH
CBZ
CC
F
CF3
CFCF2OCF3(CF2)2O
2
F3C
O  
 
 
Figure 23  Reaction Scheme 17 
 
 
 
The same reaction procedure was used as that described in Reaction Scheme 15.  Typically, 17.9 
mmoles (5.04 g) of Nα-CBZ-L-Lysine, approximately 2 g of Poly DMAP, and 60 ml of 1,1,3-
trichlorotrifluoroethane were charged to a 250 ml, three neck flask which had been previously 
flushed with nitrogen.  Subsequently, 14.6 mmols (9.72 g) of  perfluoro-2,5,8-trimethyl, 3,6,9-
trioxadodecanoyl fluoride in 60 ml of 1,1,3-trichlorotrifluoroethane was added.  The resultant 
product was a light yellow colored oil.  (Yield = 30.2 %). 
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(CH2)4
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F
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O  
 
 
Figure 24  Reaction Scheme 18 
 
 
 
The same reaction protocol was followed for CBZ deprotection of an amine as described in 
Reaction Scheme 2.  Typically, the product from Reaction Scheme 17, 2.4 mmols (2.3 g), 0.118 
g 20% PdOH on carbon, and 20 ml of methyl alcohol were added to a one arm flask.  The 
resultant product was a pale yellow oil.  (Yield = 66.9 %).   
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 Preparation of (Polyperfluoroether)-L-Lysine With Alkyl Spacer 
Perfluoro-2,5,8-trimethyl-3,6,9-trioxadodecanoyl fluoride 
 
 
 
CH
H
N C
(CH2)4
NH
CBZ
CBZ
O
O N
O
O
+  NH2(CH2)2NH2
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Figure 25  Reaction Scheme 19 
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Figure 26  Reaction Scheme 20 
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 The same synthetic procedure was used as described in Reaction Scheme 13.  Typically, 3.9 
mmols (0.26 ml) of ethylenediamine and 10 ml of anhydrous terahydrofuran were charged to a 
250 ml, three neck flask which had been previously flushed with argon.  Subsequently, 3.9 
mmols (2.00 g) of Nα,Nε-di-CBZ-L-lysine-N-hydroxysuccinimde ester in 50 ml of anhydrous 
tetrahydrofuran was added dropwise with vigorous stirring.  After 20 minutes, a white precipitate 
formed.  The reaction mixture was further diluted with 100 ml of 1,1,3-trichlorotrifluoroethane 
and stirred vigorously.   Then 3.0 mmols (1.99 g) of perfluoro-2,5,8-trimethyl-3,6,9-
trioxadodecanoyl fluoride in 50 ml of 1,1,3-trichlorotrifluoroethane was added dropwise with 
vigorous stirring over a 1 hour  time period under argon.  After 24 hours, the mixture was 
vacuum filtered and the filtrate then concentrated.  The product was washed thoroughly with 
acetone and resulted in a clear, pale yellow oil.  (Yield = 48.2 %). 
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Figure 27  Reaction Scheme 21 
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 The same reaction protocol was followed for CBZ deprotection of an amine as described in 
Reaction Scheme 2.  Typically, the product from Reaction Scheme 20, 0.70 mmols (0.8 g), 0.062 
g 20% PdOH on carbon, and 15 ml of methyl alcohol were added to a one arm flask.  The 
resultant product was a yellow oil.  (Yield = 75.5 %).   
 
 
Preparation of Fluoroalkyl Functionalized Quinine 
 
 
 
N
CH3O
HO N THF / N(CH2CH3)3
+ C Cl
O
(F2C)6F3C
N
CH3O
O N
C
O
(F2C)6F3C
+  (CH3CH2)3NH
+Cl-  
 
 
Figure 28  Reaction Scheme 22 
 
 
 
 In a typical experiment, 9.2 mmols (2.98 g) of quinine and 9.2 mmols (1.28 ml) of 
triethylamine in 30ml dry tetrahydrofuran were charged to a 3 neck, 250 ml flask which had been 
previous flushed with nitrogen for 15 minutes.  Subsequently, 9.2 mmols (2.28 ml) 
pentadecaperfluorooctanoyl chloride in 10 ml dry tetrahydrofuran was added dropwise with 
vigorous stirring for 30 minutes at room temperature.  The contents of the reaction mixture were 
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 filtered under vacuum and the filtrate collected and concentrated.  The resultant white, solid 
product was recrystallized from a 1:1 tetrahydrofuran/pentane solution.  (Yield =  75.0 %).   
 
 
Preparation of Fluoroalkyl Functionalized Quinidine 
 
 
 
N
CH3O
HO N THF / N(CH2CH3)3
+ C Cl
O
(F2C)6F3C
N
CH3O
O N
C
O
(F2C)6F3C
+  (CH3CH2)3NH
+Cl-  
 
 
Figure 29  Reaction Scheme 23 
 
 
 
  The purpose of preparing this compound was to determine if this material showed 
preferential binding to the opposite enantiomer than quinine.  The same synthetic procedure was 
used for the preparation of this reagent as in the preparation of the fluoroalkyl functionalized 
quinine.  In a typical experiment, 6.4 mmols (2.07 g) of quinidine, 6.4 mmols (0.89 ml) 
triethylamine, and 6.4 mmols (1.59 ml) of pentadecaperfluorooctanoyl chloride were used.  The 
product obtained was a white solid.  (Yield = 36%).   
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 Preparation of a Silicone Functionalized Quinine 
 
 
 
N
CH3O
HO N
N
CH3O
HO N
SiOSiOSiCH3
CH3
CH3 CH3
CH3
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CH3
CH3 CH3
CH3
CH3
CH3
+
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C6H5(CH3)
 
 
 
Figure 30  Reaction Scheme 24 
 
 
 
 In a typical experiment, a 3 neck, 250 ml flask is heat dried and flushed with nitrogen for 
15 minutes.  To the flask is added 15.4 mmols (4.99 g) quinine, 18.5 mmols (4.11 g) 
1,1,1,3,3,5,5-heptamethyltrisiloxane, 0.0155 mmols platinum catalyst, and 50 ml dry toluene.  
The reaction mixture is again flushed with nitrogen and placed under a nitrogen blanket at 65 oC.  
The reaction is vigorously stirred for 3 days with incremental amounts of catalyst added, then left 
to cool and concentrated under vacuum.  The product was purified by column chromatography 
using silica as the stationary phase and toluene as the eluent.  The resulting material was then 
stirred for 4 hours at 60 °C in toluene with activated carbon.  A pale brown oil resulted (Yield = 
37%). 
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 Table 8  Structural Characterization by 1H NMR 
 
 
Reaction Scheme Head Group Tail NMR (ppm) 
 
 
1 
 
Ne-CBZ-L-lysine methyl 
ester 
 
Fluoroalkyl 
 
1.2-1.9, 3.1, 4.6, 5.1, 6.4, 
7.2, 8.8 
 
2 
 
L-lysine methyl ester 
 
Fluoroalkyl 
 
1.2-1.9, 3.1, 4.6, 6.4, 8.9 
 
3 
 
Na-CBZ-L-lysine 
 
Fluoroalkyl 
 
1.3 - 2.1, 4.1, 
5.1, 6.9, 7.4, 9.5, 12.1 
 
4 
 
L-lysine 
 
Fluoroalkyl 
 
1.3 - 2.1, 4.2, 6.9, 12.1 
 
5 
 
Na,Ne-CBZ-L-Lysine w/ 
EDA spacer 
 
none 
 
1.2 - 2.2, 2.8, 3.2, 4.3, 5.0, 
5.7, 6.1, 7.4, 8.0 
 
6 
 
Na,Ne-CBZ-L-Lysine w/ 
EDA spacer 
 
Fluoroalkyl 
 
1.2 - 2.2, 2.8, 4.3, 5.1, 5.7, 
5.8, 6.1, 7.4, 8.0 
 
7 
 
L-Lysine w/ EDA spacer 
 
Fluoroalkyl 
 
1.2 - 2.2, 2.7, 4.2,  5.8, 
6.1, 8.1 
 
8 
 
Ne-CBZ-L-lysine methyl 
ester 
 
PHFPO 
 
1.4-1.8, 3.6, 4.5, 5.0, 6.4, 
7.2, 8.0 
 
9 
 
L-lysine methyl ester 
 
PHFPO 
 
1.4-1.9, 2.9, 3.7, 4.5, 8.0 
 
10 
 
Na-CBZ-L-lysine 
 
PHFPO 
 
1.4 - 2.0, 4.2, 5.0, 6.7, 7.2, 
8.0, 12.7 
 
11 
 
L-lysine 
 
PHFPO 
 
1.5 - 2.1, 3.4, 4.0,  6.0, 
13.6 
 
12 
 
Na,Ne-CBZ-L-Lysine w/ 
EDA spacer 
 
none 
 
1.2- 2.5, 2.9 -3.2, 3.4, 4.3, 
5.1, 5.7, 6.9, 7.3, 8.0 
 
13 
 
Na,Ne-CBZ-L-Lysine w/ 
EDA spacer 
 
PHFPO 
 
1.2- 2.5, 2.9 -3.3,  4.3, 
5.1, 5.7, 5.9, 6.9, 7.3, 8.0 
 
14 
 
L-Lysine w/ EDA spacer 
 
PHFPO 
 
1.2- 2.5, 2.9 -3.2, 3.4 - 
3.8, 4.3, 5.7, 5.9  
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 Table 8  (Continued). 
 
 
Reaction Scheme Head Group Tail NMR (ppm) 
 
 
15 
 
Ne-CBZ-L-lysine methyl 
ester 
 
PTTF 
 
0.9 - 1.8, 3.8, 4.5, 5.0, 
6.1, 7.4, 7.9 
 
16 
 
L-lysine methyl ester 
 
PTTF 
 
0.9 - 1.8, 2.3, 3.8, 4.5, 
7.9 
 
17 
 
Na-CBZ-L-lysine 
 
PTTF 
 
0.9 - 1.9, 4.2, 5.0, 6.6, 
7.2, 12.1 
 
18 
 
L-lysine 
 
PTTF 
 
0.9 - 1.9, 2.4, 3.4, 4.2, 
6.6, 12.0 
 
19 
 
Na,Ne-CBZ-L-Lysine w/ 
EDA spacer 
 
none 
 
0.9 - 2.2, 3.7, 4.3, 5.1, 
5.9, 6.6, 7.3, 8.4 
 
20 
 
Na,Ne-CBZ-L-Lysine w/ 
EDA spacer 
 
PTTF 
 
0.9 - 2.2, 4.3, 5.1, 5.7, 
5.9, 6.6, 7.3, 8.4 
 
21 
 
L-Lysine w/ EDA spacer 
 
PTTF 
 
0.9 - 2.2, 3.1 - 4.1, 4.3, 
5.9, 6.6 
 
22 
 
Quinine 
 
Fluoroalkyl 
 
1.25 - 3.42, 3.9, 4.0, 4.3, 
4.9, 5.7, 7.2-7.9, 8.6 
 
23 
 
Quinidine 
 
Fluoroalkyl 
 
1.25 - 3.42, 3.9, 4.0, 4.3, 
4.9, 5.7, 7.2-7.9, 8.6 
 
24 
 
Quinine 
 
Silicone 
 
1.25 - 3.42, 3.9, 4.0, 4.3, 
5.7, 7.2-7.9, 8.6 
 
Note:  PHFPO = polyhexafluoropropylene oxide 
           PTTF = perfluoro-2,5,8-trimethyl-3,6,9-trioxadodecanoyl fluoride 
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6.0  EXPERIMENTAL HIGH PRESSURE AND PHASE BEHAVIOR ANALYSIS 
EQUIPMENT 
 
 
 
 
6.1  W.B. Robinson Cell 
 
 
 
The W.B. Robinson Cell is a commercial apparatus which is used for the static 
measurement of a material’s phase behavior in supercritical fluids.  Unlike a dynamic system, a 
static setup is usually used to determine phase border curves in P-T space and solubility of non-
volatile compounds.  In all static systems the primary components are a high pressure, variable 
volume view cell and some form of an optic system.  A general schematic of the W.B. Robinson 
Cell is shown in Figure 31. The advantages of using this static system for cloud point evaluation 
are; 
1) phase transitions are easily determined by visual inspection 
2) sampling is not required 
3) small sample size 
4) continual adjustment of the pressure at a fixed temperature 
5) sample recovery 
 
 
 
 
6.2  High Pressure Batch Reactor 
 
 
 
A schematic of the high pressure, custom designed batch reactor used in this project is 
shown in Figure 32.  This reactor features sapphire view windows (General Ruby and Sapphire 
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 Co.) for visual observation of phase splitting, a high pressure trap (Thar Designs) for the 
collection of precipitated materials, a high pressure sampling valve with a 500 µl sample loop 
(Valco Instruments), and heating rods (Omega Engineering) contained within the body of the 
reactor.  This reactor configuration was used to experimentally measure high pressure 
equilibrium constants by assessing the fluid phase concentration of ibuprofen.  The high pressure 
system shown in Figure 33 is a modification of the reactor system shown in Figure 32.  The 
addition of the downstream depressurization/trapping system was incorporated in order to 
perform fractionation experiments.  The major components incorporated into this system 
included a back pressure regulator (Tescom) and a high pressure trap (Thar Designs). 
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Figure 31  W.B. Robinson Variable Volume View Cell 
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Figure 32  High Pressure Batch Reactor with Sampling System 
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Figure 33  Modified High Pressure Batch Reactor 
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 7.0  SOLUBILITY DETERMINATION IN SUPERCRITICAL CARBON DIOXIDE 
 
 
 
 
7.1  Introduction 
 
 
 
The solubility limits of the individual components in a supercritical fluid reaction system 
may be evaluated on the basis of their cloud points.  In its thermodynamic definition, the cloud 
point is defined as the pressure/temperature point at which the chemical potentials of each 
component in the homogeneous phase become equal.  In practice this translates for a 
supercritical fluid system to the pressure at which phase separation commences at a given 
temperature. (36)   
The enantiomers of the free acid of ibuprofen exhibit nearly identical phase behavior in 
supercritical carbon dioxide. (68)  In the form of their diastereomers, however, differences in 
phase behavior are anticipated due to energetic stabilization of the individual molecules and the 
ability of the solvent to solvate non-identical structures.  Quantitative measurements of the phase 
behavior of these diastereomers provide not only valuable information regarding the individual 
solubility of these non volatile materials in supercritical CO2, but also indicate the extent of 
difference in solubility between the two components.  This solubility difference is what allows 
for a rational design for a selective extraction process. 
There exists two methods by which to impart CO2 solubility to insoluble materials.  The 
first method is to add a miscible modifier, usually 2% to 10% v/v, to the fluid phase.  The 
purpose is not to change the overall bulk properties of the fluid phase, but rather to aid in 
dissolving the analyate into the surrounding medium.  Polar modifiers, such as methanol, form 
interactions like hydrogen bonding and induced dipole moments with the analyate to result in a 
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 more favorable partitioning of the sample into the bulk supercritical fluid phase. (40)  There are 
two distinct disadvantages of using modifiers.  First, a characteristically benign medium is 
compromised due to the introduction of an organic constituent.  Next, processing parameters are 
also altered.  Product recovery not only will involve depressurization to remove the CO2 gas, but 
also clean up of residual modifier present in the product, which increases processing costs and 
time. 
To circumvent the use of organic solvents, chemical derivatization of the agent may be 
employed in order to attain solubility in CO2.  In this research project, we have used this method 
for the purpose of maintaining a benign reaction/separation medium.  Two important chemical 
criteria must be applied to the native agents in order to render them suitable for enantiomeric 
resolutions.  First, the derivitization process must be simple to perform and reactions conditions 
mild enough so as not to induce inversion of the chiral center, thus altering the agent's natural 
selectivity.  The second criterion focuses on the structure of the natural agent itself.  Though 
there does not exist a well-defined set of rules for enantioselectivity, empirical evidence suggests 
that functionalities close to the chiral center are important in defining a rigid, steric environment 
for selectivity to be determined.  Thus, a resolving agent must possess a functionalizable group 
far removed from the chiral center.  From the list of potential candidates in Table 4, L-lysine and 
quinine were selected.  Employing similar chemical strategies as previously reported in our 
laboratories, families of functionalized L-lysines and quinines were synthesized whose structures 
are shown in Figures 34, 38, 39, and 40. (62,63,64,65,66) 
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 7.2  Experimental Procedure 
 
 
 
The W.B. Robinson Cell, as shown in Figure 31, is utilized to measure cloud points, 
which represents the boundary of phase separation.  The main feature of this apparatus is a high 
pressure, variable volume view cell, which allows for visual determination of phase separation.  
The cell is initially loaded with a predetermined sample amount and aluminum mixing beads.  
An oil supply is pumped into the bottom of the cell so as to displace the piston containing the 
sample to the top of the view cell and remove residual air.  A known amount of carbon dioxide is 
then added to the cell and the system is allowed to equilibrate at a designated temperature. 
 The cloud point is measured in the following manner.  The entire cell is pressurized until 
dissolution and then rocked via a mechanically rotating arm until thorough mixing is achieved.  
The pressure is then slowly decreased until precipitation of the sample occurs.  This may be seen 
visually by observing the transition from a clear fluid phase to one that becomes opaque. (75,78)  
Three measurements are taken for each dilution, the measurements are average, and a standard 
deviation is calculated. 
 
 
 
 
7.3  Results and Discussion 
 
 
 
The phase behavior of the chemically modified resolving agents in carbon dioxide is 
predominantly influenced by their physical architecture, thermodynamic properties, and 
carbamate formation.  The sum of these processes determines the overall solubility of an agent in 
CO2 and its reactivity in this medium.  The physical effects are based upon thermodynamic 
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 phenomena and the average weight that each parameter contributes varies between each family 
of agents.  A brief description of each parameter follows. 
 
 
 
7.3.1  Resolving Agent Architecture 
 
 
 
The chiral resolving agents described in Chapter 5 are all composed of a polar, CO2 
phobic head group and a CO2-philic tail.  The tail’s function is to impart CO2 solubility, while 
the mission of the head group is to form specific chemical interactions with a target molecule.  
The phase behavior of these modified structures will thus be dependent in part upon the 
individual contributions of each segment.  In particular, the degree of solubility of these 
compounds will vary significantly according to the extent of “CO2 philicity” exhibited by each 
molecule as a whole.  The “CO2 philicity” of these resolving agents may be adjusted as a 
function of the tail’s physical structure and chemical composition.  For example, we have found 
that fluoroether, fluoroalkyl, and silicone-based tails are effective in conveying solubility in CO2.  
The use of fluorinated esters has also been shown to be efficient in solubilizing polar materials. 
(71)  Each tail type possesses functional groups that collectively exhibit unique physical properties 
and chemical interactions to produce characteristic phase behaviors in a compressed carbon 
dioxide environment. 
In addition, the solubility of the modified resolving agents may also be adjusted as a 
function of the placement of the CO2-philic tail within the molecule.  Hancu and Beckman have 
shown that fluoroether tails (2500 MW) attached in three different positions through amidic 
linkages on anthroquinone produced isomers that showed significantly varied phase behavior. (76)  
Krukonis also observed similar behavior when investigating hydroxybenzoic acids in CO2. (36)  
 71
 Using these examples, it can be seen that the effect of resolving agent phase behavior is strongly 
dependent upon its architecture.  The challenge, then, in designing the architecture of these 
resolving agents is to produce molecules that exhibit high degrees of solubility without 
compromising the specific solute-solute interactions required for ion pair formation.  The 
thermodynamic rationale for these physical and chemical effects is described below. 
 
 
 
7.3.2 Free Energy of Mixing 
 
 
 
Solubility for a compound is favorable when the free energy of mixing, as described in 
general format below in Equation (7-1), is negative. 
∆GM = ∆HM – T∆SM                                                          (7-1) 
For ideal solutions that obey Raoult’s law, solute and solvent molecules exhibit similar 
shape and size.  For these solutions, the ideal heat of mixing is assumed negligible and the free 
energy of mixing is proportional to the entropy of mixing.  For solutions in which there is a 
significant difference between solute and solvent molecular size and the presence of inter/intra 
molecular forces, non ideal solution behavior results.  In this instance, both ∆H and ∆S deviate 
from ideal behavior.  
 
 
 
7.3.2.1  Entropy of Mixing  The entropy of mixing is dependent upon a number of factors, 
including specific interactions, differences in free volume, chain flexibility, and molecular 
weight.  The weight factor which each parameter assumes ultimately influences its phase 
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 behavior and the resultant solubility upon mixing will determine, in this instance, an agent’s 
utility in a compressed carbon dioxide environment. 
The entropy of mixing is a sum contribution of a combinatorial and residual function as 
described below in Equation (7-2).   
∆SM = ∆SC + ∆SR                                             (7-2) 
According to the lattice theory of fluids as proposed by Flory and Huggins, the combinatorial 
entropy of mixing per volume of solution may be expressed as 
∆SM = k ln Ω                                                           (7-3) 
where k is the Boltzman’s constant and Ω is the number of possible combinations in which a 
solute may be distributed among solvent molecules. (82,86,91)  In the case of relatively identical 
solvent and solute molecules, the number of possible ways in which n2 solute molecules may be 
distributed among n1 solvent molecules within a lattice consisting of no = n1 + n2 cells is defined 
by Ω as 
Ω = n !/n !n !                                                          (7-4) o 1 2
Substituting (7-4) into (7-3) gives the familiar expression for the entropy of mixing 
∆S = -k(n1lnN1 + n2lnN2)                                                    (7-5) 
where n1 and n2 refer to the number of molecules of solvent and solute, and N1 and N2 their 
respective mole fractions. (82,91) 
This expression is applicable to molecules of similar size.  Long chain molecules, though, 
have traditionally exhibited deviations from ideal behavior, and these deviations are attributed to 
variances in the entropy of mixing. (90)  In order to describe the behavior of long chain molecules, 
the solute molecule is now considered to be composed of xn2 molecules, in which x is descriptive 
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 of the number of chain segments equivalent in size to the solvent molecule.  In this manner, Ω is 
redefined as  
        Ω=[no!/(no –xn2)!n2!][(z-1)/no]n2(x-1)                                        (7-6) 
where z is the lattice coordination number and the expression for the entropy of mixing becomes  
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Applying Stirling’s approximation and subtracting the physical effect of polymer disorientation, 
equation (7-7) reduces to the following expression. (82,85,86,87,88,89,91) 
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 It is evident from equations (7-6), (7-7), and (7-8) that as a solute molecule becomes 
larger, the number of possible combinations in which to arrange the solute molecule in the 
solvent decreases as compared to a smaller sized solute.  This observation is described as a 
function of the solute’s molecular weight and determined from the relation 
                                                                        (7-9) oVMx 1/ ρ=
where M is the molecular weight, ρ is the density of the solute at the solution temperature, and 
 is the molar volume of the solvent. oV1
(89)  Thus, the larger the molecule, the smaller the overall 
entropic contribution to the free energy of mixing due to the reduced number of possible 
arrangements of solvent molecules and solute segments. 
 The combinatorial entropy of mixing represents only the external arrangement of 
molecules.  The residual entropy of mixing, on the other hand, accounts for differences in free 
volume and specific interactions between like and unlike molecules.  For example, the solubility 
of a molecule in carbon dioxide may be described as a function of the difference in free volume 
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 exhibited between CO2 and the solute.  During the solution process, carbon dioxide must 
condense and concentrate around the solute, resulting in a reduction in the free volume of carbon 
dioxide.  As more carbon dioxide molecules concentrate around the solute, the solute’s rotational 
flexibility is decreased, thereby decreasing the positive contribution to the entropy of mixing. (77)  
So as the difference in free volume between carbon dioxide and the solute decreases, an entropic 
price is paid for a favorable enthalpic contribution to the free energy of mixing.  In this instance, 
there would be a delicate balance between the favorable enthalpic effects versus the loss in 
entropy for solution to be feasible.   
One assumption made in Flory’s liquid lattice theory is that the solution configuration is 
random, in other words, the solute molecule is distributed within the solvent in a random fashion.  
If preferential interactions occur between solute and solvent molecules or between the solute 
molecules themselves, the assumption of randomness becomes less applicable depending upon 
the extent of these interactions.  Because the solution would take on a more ordered 
configuration, the entropy of mixing residual term decreases, and the resultant entropy of mixing 
is less favorable. (80, 82) 
Chain flexibility is a parameter that is influenced by solute intermolecular associations 
and is reflected by the glass transition temperature, which is utilized as a descriptive measure for 
highly flexible molecules. (79)  A smaller characteristic glass transition temperature implies a 
lesser degree of solute intermolecular forces.  Since solute intermolecular forces would reduce 
the number of possible conformations that a solute could assume, the resultant effect on the 
phase behavior of the solute in CO2 may be assumed to follow the general observation that phase 
behavior is directly proportional to the glass transition temperature.  In other words, as the Tg of 
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 a solute increases, the pressures required to solvate the solute increase, reflective of a less soluble 
material. 
Chain flexibility is also related to the free volume of the solute and is descriptive of the 
number of allowable, unrestricted solute confirmations in the solvent.  The greater the flexibility 
exhibited by the solute, the greater the disorientation of the molecule, hence, the greater the free 
volume of the solute.  Thus, the free volume difference between solute and solvent decreases 
since the free volume of the solute becomes similar to that of CO2.   
 
 
 
7.3.2.2  Enthalpy of Mixing.  The enthalpic contribution to the free energy of mixing involves 
the balance between solvent-solvent, solute-solute, and solvent-solute interactions.  This balance 
of forces is important in defining the optimal operating pressure and temperature required to 
solubilize a given solute.  The enthalpy of mixing may in general be defined by Equation (7-10) 
below. 
∆H = χ1kΤΝ1ν2                                                   (7-10) 
The term χ1 represents the interaction energy per solvent molecule divided by the quantity kT, 
and the product χ1kΤ defines the difference in energy of the solvent molecule contained within a 
solute molecule as opposed to the same solute molecule in its pure state. (80, 84)  The greater the 
difference in the interaction energy, the larger the heat enthalpy of mixing, which leads to a more 
negative free energy of mixing.  Those specific interactions that define this energetic parameter 
are described in greater detail below. 
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 Solvent-Solvent Interactions 
Carbon dioxide is a non polar fluid which exhibits very weak van der Waals forces, low 
dielectric constant, lacks a dipole moment, and does not self associate. (75)  Therefore, CO2 – CO2 
interactions are relatively weak, and the strength of the solvent -solvent interaction may be 
considered constant at a given temperature.  Though these interactions are not relatively strong, 
they nonetheless are significant due to the poor solvating properties of the gas.   
Increasing the system pressure at constant temperature is one method of overcoming the 
effect of CO2 – CO2 interactions.  By increasing the pressure, the free volume difference between 
solute and solvent is decreased potentially resulting in enhanced solubility. (92)  In addition, the 
number of non-specific interactions between solute and solvent may also increase, again 
resulting in a potential improvement in solubility.  Raising the pressure at constant temperature, 
however, is an impractical approach due to the elevated operating costs incurred at higher 
operating pressures. 
The only practical means to attempt to reduce these interactions is to raise the operating 
temperature at constant pressure.  The increased molecular motion associated with an increase in 
temperature may inhibit CO2 – CO2 interactions from forming.  Note however, that by increasing 
the temperature at constant pressure, the free volume difference between solute and solvent 
increases, resulting in an unfavorable entropic effect. (92)  Hence, there is no real effective mean 
of reducing CO2-CO2 interactions without compromising other thermodynamic factors. 
 
Solute-Solute Interactions 
Physical forces, such as London dispersion and van der Waals, play a critical role in a 
solute’s characteristic phase behavior, in particular their contribution to solute-solute 
interactions.  To decrease the effect of these interactions, a molecular structure may be designed 
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 to limit the degree of intermolecular attractions between solute molecules, namely its van der 
Waal forces.  The cohesive energy density is a parameter which is reflective of the degree of van 
der Waal forces inherently contained within a liquid/polymer.  Solution will occur when the 
intermolecular attractive forces of solute and solvent are similar, and this phenomena is reflected 
in the well know Hildebrand solubility parameter. (99)  Carbon dioxide exhibits far weaker van 
der Waal forces than traditional organic solvents and thus, solutes which can achieve the same 
limited intermolecular forces will easily solubilize in CO2. (75) 
As shown by O’Neill and coworkers, the incorporation of fluorine containing functional 
groups enhances polymer solubility. (78)  Also shown by Yee and Fulton, the fluoro analogue of 
1-butanol exhibited higher solubility than 1-butanol.  They rationalized that because fluorines are 
so highly electronegative, they exhibit repulsive forces, thereby decreasing solute intermolecular 
attractions. (95)  Thus, molecules that possess fluorine containing functional groups, such as 
poly(perfluoroethers), CF2, and CF3 groups, exhibit a smaller degree of attractive van der Waal 
forces, reflective of a low cohesive energy density which promotes dissolution into compressed 
carbon dioxide.   
Chemical forces also play a significant role in a solvent’s ability to solvate a given solute.  
One of the largest contributions to solute-solute interactions, hence potential decreases in 
solubility, is hydrogen bonding.  The model compounds investigated in this research project 
possess many locations for hydrogen bonding within their physical structures.  Ironically, the 
molecular structure of these molecules must fulfill both the requirements of solubility and 
hydrogen bonding.  On the one hand, limited solute-solute interactions are needed to bring the 
resolving agents readily into solution.  In contrast, diastereomeric ion pairing is based on at least 
one hydrogen bond, therefore, functional groups which participate in hydrogen bond formation 
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 must be present.  Both enthalpic and entropic penalties are paid due to the formation of a more 
ordered solution configuration and subsequent decreases in solvent-solute interactions  
Hydrogen bonding in supercritical CO2 has been well documented.  O’Shea and 
coworkers utilized UV-visible spectroscopy to examine hydrogen bonding in the tautomeric 
equilibrium of 4-(phenylazo)-1-naphthol. (93)   Infrared spectroscopy was employed to investigate 
hydrogen bonding with pyrrole by Hyatt, and the degree of intermolecular H-bonding with 
certain alcohols and their fluoro-analogues were investigated by Yee and Fulton. (94,95,97)  Sigman 
and coworkers spectroscopically observed H-bonding in the solvatochromic indicators, 4-
nitroaniline and N,N-diethyl-4-nitroaniline. (96)  Van Alsten and coworkers examined the role of 
hydrogen bonding on solubility when cosolvents, such as methanol, were added with polycyclic 
solutes. (36)   
Hydrogen bonding has been recently investigated with polymer systems in CO2.  
Kazarian and coworkers observed H-bonding in PVAc and Nylon 6. 71  Takishima and 
coworkers identified intramolecular and intermolecular hydrogen bonds, in which the oxygen of 
a hydroxyl functional group was bound to other hydroxy or ether oxygen atoms in PEG, PPG, 
and PEGDME polymers. (75)  O’Neill and coworkers found that the primary alcohol groups in 
PEO polymers undergo hydrogen bonding, and the net effect was a dramatic increase in the 
operating pressure required to solvate the polymer. (78) Briscoe and Kelly observed hydrogen 
bonding occurring between an N-H and C=O functionalities in polyurethanes. (98)  Thus, the 
common conclusion found in all of these studies, with the exception of those utilizing modifiers, 
is that the net effective solubility was penalized in systems that exhibited hydrogen bonding.   
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 Solvent-Solute Interactions 
An increase in the number of favorable carbon dioxide-solute interactions may be 
accomplished by incorporating functional groups, which exhibit a strong CO2 interaction.  
Promoting solute-CO2 interaction, via Lewis acid-base pairing, was shown by Kazarian and 
coworkers to be effective with electron donating groups such as carbonyl functional groups. 
(71,76,77)  In a recent study by Sarbu and Beckman, a non fluorous CO2-phile ether carbonate 
copolymer was synthesized and compared against a traditional poly(perfluoro) ether based 
polymer.  Reported solubility measurements of these polymers indicated that the ether carbonate 
copolymer exhibited a higher degree of solubility than that of the poly(perfluoro) ether based 
polymer.  These results give a strong indication of the preferential interaction of carbon dioxide 
for carbonyl functionalities. (79)  A strong penalty, however, against the entropy of mixing is paid 
in terms of the difference in free volume.  Though strong solvent-solute interactions contribute to 
a negative enthalpy of mixing and more favorable free energy of mixing, the effect is countered 
by a decrease in the entropy of mixing.  By forming interactions, the randomness of the solution 
is decreased, thereby, rendering a less positive contribution to the entropy of mixing.   
 
 
 
7.3.3  Carbamate Formation 
 
 
 
 Primary amines can react with carbon dioxide to form carbamate molecules as shown 
below in Equation (7-11). 
 
RNH2  +  CO2 NR C
O
OH
H
-
+
NR C
O
OH
H
     (7-11) 
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 Carbamates have traditionally served as nitrogen protecting groups in organic synthesis. 
(85)  N-substituted carbamic acids are also relatively unstable molecules and can break down into 
carbon dioxide and its respective amine. (85)  The formation of this complex is dependent upon 
many factors, which include CO2 and amine concentration, pKa of amine, temperature, and 
system pressure.  Carbamate formation is also an equilibrium reaction in which the concentration 
of available amine is a function of temperature.  For example, previous studies by Beckman and 
Diaf, who investigated the extent of carbamate formation occurring with free amines in styrene 
copolymers, have shown that in supercritical CO2 the decomposition temperature of carbamate 
complexes occurs at approximately 55 oC. (69) 
 Empirical evidence suggests that the solubility of carbamate complexes formed from the 
resolving agents investigated in this project will be governed by the solubility of the CO2 philic 
tail of the resolving agent.  A largely CO2 philic tail has the potential to solvate a carbamate 
complex since the carbamate portion of the molecule comprises only a small fraction of the 
molecule.  Conversely, the carbamate complex will make a significant contribution to the 
solubility of the agent as a whole with agents that exhibit poorer solubility.  Solubility of the 
agent, then, will be partially determined by the balance of the solvent interacting between the 
polar head group and the CO2-philic tail of the agent molecule. 
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 7.3.4  Quinine and Quinidine  
 
 
 
Carbon Dioxide Philicity and Chiral Orientation 
 
Quinine was modified with a fluoroalkyl and a silicone tail as shown in Figure 34, 
structures 1 and 2.  These tails exhibit low cohesive energy densities and are anticipated to 
impart favorable solubility to the native quinine based molecules.  Although the silicone tail 
possesses a higher molecular weight than its fluoroakyl functional analog, the silicone 
derivatized agent exhibited cloud point pressures significantly below that of the fluoroalkyl.  
Here, although the use of a higher molecular weight silicone structure is entropically less 
favorable, the molecule is on balance more CO2 philic and hence, dissolves at a lower pressure.  
One observation to note is that these tails are attached at different locations on the quinine 
molecule.  Entropic effects pertaining to the ability of the agent to self associate and restrictions 
upon its rotational flexibility are expected to differ between the two agents.  These effects, 
however, are difficult to independently discern given the high enthalpic favorability contributed 
by the silicone versus the fluoroalkyl tail. 
 Quinidine was derivatized in order to evaluate if the there is any effect on the solubility 
of a molecule as a function of its chirality.  Racemic mixtures would not ordinarily be expected 
to exhibit differences in solubility in carbon dioxide, since it is a non chiral medium.  For 
example, the phase behaviors of the enantiomers of ibuprofen were measured independently and 
no difference in phase behavior was evident.  However, structure 3 in Figure 34 appears to show 
a significant difference in phase behavior from structure 2, which is its chiral inverse.  The 
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 quinidine based resolving agent exhibits a marked decrease in solubility as compared to its 
quinine based analog. 
In this case, an argument may be made for differences in solute-solute interactions.  
Phenyl groups can undergo π−π bonding, producing structures which can orient themselves in a 
stacked configuration, thus altering the phase behavior in comparison to the same molecules 
randomly distributed in solution.  Steric effects may also influence solute-solute interactions.  As 
seen in molecules 2 and 3, in close proximity to the phenyl group lays the fluoroalkyl tail.  This 
tail may have the potential to interfere in the ability of a molecule to orient itself with respect to 
its neighboring molecule, depending upon its three dimensional alignment in space.  
 The preference of the quinidine analogue to self associate through hydrogen bonding is 
evident in its phase behavior.  The absolute value of the free energy of mixing is negatively 
impacted from both an entropic and enthalpic viewpoint.  Self association impacts the entropic 
contribution by causing a decrease in the rotational flexibility and subsequently the randomness 
of the solution.  Higher solute-solute interactions as compared to the quinine analogue produces 
a more positive enthalpy of mixing.  Hydrogen bonding has been noted to have a significant 
impact upon phase behavior as observed with isomers. (75, 77, 78)  This leads to the conclusion that, 
though the quinine/quinidine agents are structurally similar, intermolecular interactions dominate 
the phase behavior and, thus, distinctly distinguishes the two molecules from one another in CO2. 
 The error associated with each point on the cloud point curve was computed as a standard 
deviation.  The standard deviations ranged from ± 30 psi to ± 262 psi.  Based upon empirical 
evidence in our laboratories, computed standard deviations in the range of 50 to 300 psi are 
typical and the magnitude is operator dependent.  Larger standard deviations were observed with 
the quinidine fluoroalkyl derivative.  This is attributed to the cloud points observed near the 
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 pressure limitations of the equipment.  For this family of agents, it was also observed that the 
higher the solubility of the agent, the lower the calculated standard deviations.  This trend was 
only observed among the quinine family.  The range of standard deviations for agents of the 
various lysine families were relatively consistent, from approximately ± 10 to ± 130 psi. 
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 7.3.5  L-Lysine  
 
 
 
Comparison of Tail Length and Placement 
 
 L-lysine possesses three potential sites for chemical derivitization located at the α and ε 
amines and the α carboxy functional group.  Nine derivatives were generated in order to 
investigate any effect attributable to tail length and tail placement.  Tail length was evaluated for 
one fluoroalkyl ( MW = 432) and two perfluoroether tails differing in the number of repeat units 
(2 units versus 14 and a MW of 664 versus 2500 respectively).   
 
 
 
Tail Length.  Structures 4, 7, and 10 in Figure 35 is an interesting example of determining an 
optimal chain length for a given head group.  By reason of molecular weight, structure 10 would 
be expected to result in the most soluble compound, followed by molecules 7 and 4.  What is 
observed, however, is that molecule 10 is actually the least soluble and 7 the most soluble.  
Molecule 10 possesses the fluoroalkyl tail, which is less “CO2 philic” than the corresponding 
fluoroether chains, so its lower solubility in CO2 is expected.  Comparing molecules 4 and 7, it is 
evident that entropic predominated over enthalpic effects. Though 4 possesses a greater gain in 
“CO2 philicity”, it is encumbered by its higher molecular weight as opposed to the lower 
molecular weight analog. 
 Examining molecules 5 and 8 in Figure 36, the same scenario was observed.  Molecule 5, 
which possesses a higher degree of “CO2 philicity” is less soluble than molecule 8.  Again the 
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 entropy of mixing predominates over solute –CO2 interactions as a result of molecular weight 
differences.  The same consistent result was observed for molecules 6 and 9 in Figure 37.   
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Figure 37  Comparison of Tail Length for L-Lysine Diamide Derivatives 
 
 
 
Tail Placement.  The next step was to investigate if tail placement affected the solubility of 
these agents in carbon dioxide.  Comparing structures 4, 5, and 6 in Figure 38, significant 
deviation in phase behavior is observed with molecule 6.  This molecule has two unique features 
as compared to molecules 4 and 5 in this family of agents which include; 1) two free primary 
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 amines and 2) a two carbon spacer resulting in an increase in the molecular weight and polarity 
of the agent. 
The existence of the two free primary amines presents the potential of carbamate and self 
association through hydrogen bond formation in high pressure CO2.  In addition, two more 
hydrogen bonding localities (two amides) have been incorporated into the molecule.  These 
factors could possibly make a substantial contribution to the observed phase behavior.  By 
increasing the potential for solute-solute interactions via hydrogen bonding, coupled with 
unfavorable solvent-solute interactions via carbamate formation, the observed pattern in phase 
behavior is reasonable for this molecule.   
Intermolecular interactions of the α and ε amines of the lysine head group with the 
carbonyl groups would be strongly influenced by the pKa of the amines.  The pKa of the α 
amine of the natural amino acid is referenced as 9.2 and that of the ε amine as 10.8. (72)  The 
higher the basicity of the amine, the greater its affinity for a Lewis acid counterpart.  Thus, it is 
anticipated that the ε amine would not only participate to a greater extent in solute intermolecular 
interactions than the α amine, but also in carbamate formation which is observed between 
structures 4 and 5 in Figure 38.  In this case, heavy entropic and enthalpic penalties are paid in 
spite of the presence of a highly “CO2 philic” tail.  The lysine head group, though its contribution 
to the total molecular weight is small, dominates the molecule’s phase behavior due to its 
probable interactions with itself and the surrounding medium. 
 Examination of structures 4 and 5 in Figure 38 reveals a deviation in phase behavior as 
the concentration of the species increases.  Comparison of the two molecules shows that 
structure 4 possesses an ester functional group and structure 5 a carboxy functional group.  
Because carbonyl functionalities have been shown to favorably interact with CO2, it is 
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 anticipated that structure 4 would exhibit a lower cloud point curve than structure 5.  Instead, the 
reverse trend is observed experimentally.  As rationalized above, structure 4 has the greater 
potential to form intermolecular associations.  It can be postulated that as the concentration of 
agent increases, larger intermolecularly attached complexes are formed, resulting in an increase 
in the macroscopic weight of the agent.  This effect results in a decrease in solubility due to the 
formation of an entropically unfavorable complex.  However, as will be described next, this 
behavior is not consistent with its other analogues.  Thus, the reason why this effect is observed 
is unknown. 
 A comparison of the analogous molecules 7 and 8 in Figure 39 shows a different 
result.  The cloud point curves exhibited by molecules follow the expected phase behavior 
pattern.  In comparison to molecule 8, molecule 7 possesses a greater number of CO2 philic sites 
(ester versus carboxy acid), thus, promoting more favorable solute-solvent interactions and 
improved solubility.  The primary structural difference between the 4 and 7 and 5 and 8 pairs is 
the fluoro tail attached to the lysine head group.  As stated previously, the tail containing 2 repeat 
units imparted better solubility than the fluoro tail with 14 repeat units.  As expected, entropic 
forces obviously predominate due to the large molecular weight increase, but do not fully explain 
why molecules 4 and 7 exhibit deviant behavior.  Also in Figure 39, the same relative phase 
behavior for the diamine analogue as a function of tail placement for structure 9 is observed as 
that for molecule 6 in Figure 38. 
 The last series of fluorinated L-lysine derivatives to be investigated are those that have 
been modified with an eight carbon, fluoroalkyl tail.  From phase behavior measurements made 
in our laboratories, it has been found that fluoroalkyl tails exhibit significantly less solubility 
than either tails composed of silicone or fluoroether functional groups.  This phenomenon is 
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 confirmed in Figure 40.  Of the three modified molecules, possessing the same head group as 
those in Figures 38 and 39, only one agent was soluble in CO2 (within the pressure limits of the 
testing apparatus – 8,000 psi).  This agent, molecule 10, exhibits the least solubility of the three 
tails and possesses the greatest similarity to a hydrocarbon, which is approximately 3 times less 
soluble in carbon dioxide than the fluoro – substituted analog. (52)   The influence of the chemical 
properties of the head group on molecules 11 and 12 are important enough to render these 
molecules insoluble in carbon dioxide.  The fluoroalkyl tail does not impart enough of a 
favorable enthalpic benefit to solubilize these molecules. 
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Figure 38  PHFPO L-Lysine Derivatives 
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Figure 39  PTTF L-Lysine Derivatives 
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Figure 40  Fluoroalkyl L-Lysine Derivatives 
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 7.4  General Phase Behavior of L-Lysine and Quinine Resolving Agent Systems 
 
 
 
Examination of the previous experimental solubility data shows a characteristic pattern of 
phase behavior for solid-supercritical fluid systems.  Though the agents, ibuprofen, and carbon 
dioxide show marked differences in molecular architecture, polarity, and molecular weight, the 
same broad phase behavior is observed.  Below in Figure 41 is shown a general phase behavior 
diagram for the resolving agent systems evaluated in Figures 34, 38, 39, and 40. 
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  The temperature at which the phase behavior of these resolving agent derivatives were 
tested was 30-32 oC (Controller temperature was set to 31 oC ± 1 oC ).  This temperature range 
represents a point approximately at the critical temperature of carbon dioxide.  As a result, the 
following P-x relationship at constant temperature occurs and is described in greater detail 
below. 
 
A :  Vapor-Pure Solid Equilibrium 
B:  Fluid-Pure Solid Equilibrium 
C:  Single Phase Fluid 
D:  Vapor-Fluid Equilibrium 
E:  Vapor Pressure of Pure Solid 
 
 At pressures significantly below the critical pressure of CO2, an equilibrium between 
pure solid and carbon dioxide vapor exists.  As the system pressure is increased, the SLV (pure 
solid/liquid solution/vapor) line is intersected, which is descriptive of a three phase equilibrium, 
and forms a boundary between regions B and A, and D and A.  Since the operating temperature 
is slightly below the critical pressure of CO2, the SLV line is observed to occur at pressures that 
are slightly below the extrapolated vapor pressure of pure CO2 at that temperature. 
 If the overall mixture composition is greater than the liquid phase composition, then by 
increasing the pressure an equilibrium between a fluid solution and pure solid exists.  This is 
indicated in Figure 41 as region B.  If, however, the overall mixture composition is less than the 
liquid compostition, than an equilibrium between nearly pure CO2 and a fluid solution results as 
indicated by region D.  One critical point also exists in this region.  The highest pressure point on 
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 the fluid-vapor envelope is the fluid-vapor critical point.  Finally, region C in Figure 41 
represents a region where a single phase fluid solution would exist. 
The resolving agents investigated in this research project exhibited very low solubility, 
therefore, the mole % of agent in CO2 is small and phase behavior characteristic of the dilute 
solution range is expected.  Thus, fluid-pure solid equilibrium phase behavior will not be 
observed.  In addition, the concentration of solids in this region is most likely dilute enough, so 
that the physical effects, such as melting point depression, will also not be observed. (36,80) 
One important experimental observation requires mention.  Upon depressurization, 
precipitation of solute is evident at higher pressure than visual bubble formation.  This 
observation suggests that the fluid-vapor envelope is small and the fluid-vapor critical point 
cannot be accurately measured by the current system.   
 
 
 
 
7.5  Conclusion 
 
 
 
 The use of natural products for pharmaceutical processing in a supercritical carbon 
dioxide medium presents a substantial challenge due to the poor ability of carbon dioxide to 
solubilize polar materials.  Derivatization of these materials presents an avenue with which to 
move these insoluble materials into an environmentally benign reaction/processing environment.  
Careful consideration must be given to how and where a native molecule is derivatized and, 
ultimately, how will it affect the reaction process.   
Thermodynamic mixing rules describe how a derivatized molecule will behave and 
finding a balance between entropic and enthalpic effects dictates how the molecular architecture 
 98
 of the molecule is to be constructed.  In summary, functional groups which exhibit low cohesive 
energy density and do not self associate are well suited for the CO2-philic portion of the 
molecule.  Unfortunately, hydrogen bonding functional groups are required at the head group in 
order to bind to the target ibuprofen molecule.  Minimization of hydrogen bonding 
functionalities in the head group which are not participating in complex formation improves the 
likelihood of greater agent solubility.  
The next step in this investigation is to test the ability of these molecules to form ion pairs and 
again how these molecules collectively behave in a supercritical carbon dioxide environment. 
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 8.0  MEASUREMENT OF EQUILIBRIUM CONSTANTS IN CO2 
 
 
 
 
8.1  Introduction  
 
 
 
In order to resolve the enantiomers of ibuprofen, the thermodynamic equilibrium 
resulting from the formation and stability of the salt complexes in a saturated carbon dioxide 
medium requires evaluation.  The relative value of the equilibrium constant will presumably 
indicate to what extent salt formation occurred and whether selectivity of the resolving agent has 
been preserved compared to its selectivity in organic solution.  Based upon these observations, 
the resultant salts formed from the complexation of ibuprofen and resolving agent in carbon 
dioxide will either be: 
 
• separated as a function of phase behavior differences in P-x space and the natural 
affinity of the resolving agent for each enantiomer of ibuprofen. 
• separated only as a function of their phase behavior differences in P-x space. 
• inseparable due to the formation of eutectics, loss of selectivity of the resolving 
agent, and/or possessing similar phase behavior in P-x space. 
 
Highly selective agents are expected to yield better separation results owing to the greater 
difference in solubility between free ibuprofen and unbound resolving agent as opposed to a 
diastereomeric salt pair.  In addition, higher selectivity also implies that an excess of one 
enantiomer of ibuprofen will be present.  The separation of bound ibuprofen from unbound 
ibuprofen depends then not only upon the reactivity of each species and their resultant 
 100
 concentration in solution, but also on their collective phase behavior.  The reactivity of each 
species describes how much of each species will form, thus indicating how much of each 
enantiomer will remain unbound.   
The greater the disparity in phase behavior between unbound agent, salt complex, and 
unbound ibuprofen, the likelihood of a better separation.  Ideally, if an agent retains its 
selectivity in CO2, an efficient separation process may be constructed.  As discussed in Chapter 
7, the phase behavior of the modified resolving agents varied as a function of the “CO2 philic” 
tail that was attached to the natural agent.  The agents possessing fluoroether tails exhibited 
miscibility pressures well below that of free ibuprofen.  Conversely, those agents which 
possessed a fluoroalkyl tail exhibited miscibility pressures well above that of ibuprofen.  The 
phase behavior of the resultant salts formed from these modified agents is also anticipated to be 
heavily influenced by the nature of the tail attached to the resolving agent.  For example, those 
modified agents which are marginally soluble in CO2 are intuitively not expected to produce a 
more soluble salt complex.  Likewise, those agents that exhibit higher solubility are more likely 
to produce soluble salt complexes. 
Basing the selectivity of the resolving agents on their behavior in organic media, 
however, cannot be applied in a direct manner to supercritical carbon dioxide.  Not only are 
separations of this type solvent dependent, but also are usually performed in the presence of a 
polar component, whether it is the solvent itself or a modifier.  Due to the extreme non polar 
nature of CO2, deviations from currently reported literature data are anticipated.  In addition, 
chemically modified agents will be used, and these modifications have the potential to affect the 
binding capacity of the resolving agents thereby reducing the expected selectivity of the 
resolving agent. 
 101
 8.2 Ion Pair Formation and Equilibrium 
 
 
 
As described previously, the enantiomers of ibuprofen are industrially resolved using 
diastereomeric crystallization.  Thus, the formation of ion pairs and their resultant solubility is 
the primary mechanism by which separation occurs.  This mechanism is verified from 
crystallographic studies of ibuprofen lysinate complexes.  From these studies, it was found that a 
hydrogen bond is formed between the carboxylic acid of ibuprofen and the ε amine of lysine. (55, 
56, 57, 58, 59, 60,61)  The comparison then between the known industrial method and the method using 
CO2 as proposed in this research project is highly dependent upon the reactivity of these 
molecules in their respective solvents.  This becomes primarily a comparison between an 
ethanol/H2O solution, which is used industrially, and carbon dioxide. 
Application of diastereomeric crystallization in high pressure carbon dioxide is presented 
schematically in Figure 42.  Initially ibuprofen (shown as one enantiomer in this schematic) and 
resolving agent are present as free species in the solid phase, which is represented as the area 
under the straight line in the schematic.  Upon pressurization of the CO2 fluid phase, resolving 
agent and ibuprofen begin to dissolve into the CO2 bulk fluid phase and react to form an ion pair 
complex.  Dissolution and reaction in this schematic are not meant to imply that these events 
happen separately, but probably occur simultaneously.  In the bulk fluid phase, there will be at 
least three species present (or five if both enantiomers are present).  As discussed in Chapter 7, 
the solvation of higher molecular weight species is entropically disfavored and may potentially 
result in the precipitation of that particular species from solution.  Precipitation is a physical 
process in which a phase change occurs so that the reaction solution becomes a two phase 
system.  Most precipitations begin slowly, accelerate, and then slow down again. (85)  If the salt 
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 were to precipitate from the bulk phase, more salt will form according to LeChatelier’s principle, 
resulting in a dynamic process with the quantity of salt precipitated dependent upon time.  
Finally, after an infinite amount of time, all resolving agent and ibuprofen will be bound and 
precipitated from solution. 
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 Figure 42  Diastereomeric Crystallization in High Pressure CO2 
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 The association or dissociation of ions to form ion pairs is dependent upon the polarity of 
the solvent in which they exist.  For example, in solvents of low polarity ions tend to associate 
themselves into pairs, and this affinity of the cation for the anion is also an observed solvent 
dependent phenomenon. (18,81)  These ion pairs may exist in two distinct forms, as either the 
direct contact or solvent separated form.  In the direct contact form, no solvent molecules are 
spatially located between the two species, while a solvent separated pair has a solvent molecule 
separating the two.  Both of these ion pair types may be detected spectroscopically. (79) 
Whether direct contact or solvent separated, the interaction between the resolving agent 
and ibuprofen is based upon the reaction of an acid and a base.  Though the reaction takes place 
in a non polar medium, the stability of that resultant ion pair may not be favorable.  Therefore, 
equilibrium measurements are necessary to evaluate whether CO2 serves as a suitable medium 
for reactions of this type. 
A general equilibrium model is employed in an attempt to determine the predominant 
observable equilibrium reaction.  Reaction systems of this type exhibit many equilibria, 
including those for dissolution, main reaction, side reactions, nucleation, and precipitation.  
Kinetic effects may also be present, particularly with those processes that are typically slow to 
reach equilibrium, such as precipitation processes.  The current experimental setup does not 
allow for the identification and measurement of any one single equilibrium.  Instead, the 
dominant equilibrium is measured and a simple model is derived in order to correlate these 
measured effects.  The following assumptions are used for the construction of a simple model 
equilibrium equation. 
• It is assumed that the observed equilibrium is readily established based upon the 
nature of the interaction between ibuprofen and the resolving agent.  The association 
 105
 formed from this interaction is likely an ion pair possessing a hydrogen bond. (55, 56, 
57, 58, 59, 60, 61)  Hydrogen bonding, functioning as the sole attractive force, has been 
shown to be sufficient for optical resolution using liquid chromatography. (86)  
Hydrogen bonds are also known in solution to rapidly form and dissociate.  For 
example, the mean lifetime of such a bond is on the order of 10-12seconds. (82)  Thus, 
ion pair formation is expected to occur rapidly and equilibrium readily established 
within the designated experimental time frame of two hours.   
• The molar ratio of total ibuprofen to resolving agent that will be used in these 
experiments is 1:1.  Thus, for every mole of ibuprofen there is one mole of agent 
available for complexation. 
• Dimerization of ibuprofen is insignificant. 
• The rate of precipitation, if it occurs, is assumed to be significantly less than either 
the rate of dissolution or the rate of ion pair formation.  As noted by Freiser and 
Fernando, a slow equilibration of solid and solute exists during precipitation 
phenomena, the duration dependent upon the nature of the solute and solvent. (80) 
 
The equilibrium expression of one mole of an enantiomer of ibuprofen reacting with one 
mole of resolving agent may be written as 
 [ ] [ ] [ ] SPSaltIR sol →→+ ←←                                                         (8-1) 
where [R] is the concentration of resolving agent, [I] is the concentration of ibuprofen, [Salt]sol is 
the concentration of salt in solution, and SP is the number of moles of salt precipitated from 
solution.  Thus, the equilibrium constant is expressed as follows. 
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[ ]
[ ][ ]IR
Salt sol
eqK =                          (8-2) 
The total amount of salt produced at a given time is shown by the following mass 
balance, 
[ ] [ ] [ ]IVIVSPSaltV osol *** −=+                                            (8-3) 
where [I]o is the initial concentration of ibuprofen and V the reactor volume. 
The mass balance expression for one mole of ibuprofen binding to one mole of resolving 
agent is [ ] [ ] [ ] [ ]RVRVIVIV oo **** −=−                           (8-4) 
and dividing by the volume and rearranging, Equation (8-4) becomes 
[ ] [ ] [ ] [ ]IIRR oo +−=                           (8-5) 
Substituting in Equation (8-2) with the expression for[Salt]sol from Equation (8-3), and 
dividing by the volume Equation (8-2) becomes 
[ ][ ] [ ] [ ]IIVSPIRK oeq −=+                                    (8-6) 
Substituting Equation (8-5) into Equation (8-6) and assuming [I]o = [R]o 
[ ] [ ] [ ] 02 =+−+ VSPIIIK oeq                         (8-7) 
If no precipitation occurs or the rate of precipitation is significantly slow relative to the 
measurement of equilibrium then the equilibrium expression reduces to 
[ ] [ ]
[ ]2I
IIK oeq
−=               (8-8) 
 
 107
 If precipitation is significant, then the equilibrium expression becomes 
[ ] [ ]
[ ]2I V
SPII
K
o
eq
−−=               (8-9) 
 
and equations (8-8) and (8-9) represent the upper and lower boundaries of the equilibrium 
constant.  In this series of experiments precipitation was not visually observed.  This implies that 
either precipitation did not occur or the rate of precipitation is significantly slow.  In either case, 
the SP/V term in Equation (8-9) is assumed negligible and the model equilibrium equation 
reduces to Equation (8-8). 
 
 
 
 
8.2  Experimental 
 
 
 
The quantity of free ibuprofen versus bound ibuprofen was measured by an indirect 
method.  This method was developed as an alternate to direct in situ measurements, since a high 
pressure UV or IR apparatus was not available.  A qualitative experiment was designed to 
determine equilibrium constants to a rough order of magnitude.  The results of these experiments 
are shown in Figures 43 to 52.  Equilibrium constants for each individual enantiomer of 
ibuprofen were measured independently from one another.  The purpose of designing the 
experiment in this manner was to be able to: 
 
• Distinguish differences in equilibration time between the two enantiomers and the 
resolving agent. 
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 • Distinguish differences in the selectivity of the resolving agent for the two 
enantiomers of ibuprofen. 
 
Typically, a 1:1 mole ratio of the resolving agent to either enantiomer of ibuprofen is 
loaded into a high pressure cell, charged with CO2 to a pressure of 5800 psi (which is a pressure 
above the phase boundary curves for each of the components), and vigorously stirred.  Samples 
of the fluid phase are then taken at specified time intervals.  To take a sample, a high pressure 
sampling value (Rheodyne, Inc.) is turned to the load position.  To recover the sample, the value 
is manually switched and the sample is collected in a 5 ml n-hexane liquid trap and washed with 
additional 1ml n-hexane through the flush port ( 0.4 ml dead volume).  Hexane was chosen 
because it is also a nonpolar medium, and ibuprofen is soluble in this medium while the native 
agents and the corresponding salt complexes are not.  Thus, the equilibrium quantities of free and 
unbound species are expected to remain similar and what material is collected in the hexane 
phase is composed primarily of unbound ibuprofen.  
The sample is then filtered (Millipore) to remove solid particulates and the solvent 
evaporated.  The solid sample is then redissolved in the HPLC mobile phase for analysis.  The 
flush port on the reactor is then dried with an air stream to ensure that all solvent has been 
removed from the sample loop prior to taking the next sample.   
The samples were analyzed for unbound ibuprofen by a Hewlett Packard Series II 1090 
HPLC unit using a Chiracil-ODH (Chiral Technologies) chiral column.  The mobile phase 
consists of 98% hexane: 1.9% 2-propanol: 0.1% TFA, and the analysis was run with a flow rate 
of 0.8ml/min at 38°C.  The run time for sample analysis was 8 minutes.  The concentration of 
each enantiomer was obtained by comparing the peak area from the HPLC chromatogram 
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 against a standard curve, and the equilibrium constant was calculated according to Equation (8-
8).   
Bound species are also assumed not to significantly dissociate due to the observation that 
ions will aggregate in non polar media.  This assumption was verified for the salt complexes in 
carbon dioxide.  In this experiment, the salt complexes were formed prior to introduction into the 
batch reactor.  The cell was pressurized to 7000 psi and gently stirred for 2 hours, representative 
of the time allotted for equilibrium measurements.  The stirring was stopped for 30 minutes and 
samples of the fluid phase were taken and analyzed by HPLC.  The same analytical procedure 
was employed except that TFA was omitted from the mobile phase.  The total ibuprofen content 
was measured and results indicated that a maximum of 5% dissociation occurred for most of the 
salts.   
 
 
 
 
8.3 Results and Discussion 
 
 
 
8.3.1  The Quinine Family 
 
 
 
The equilibrium data for the quinine series of resolving agents is presented in Figures 43, 
44, and 45.  The measured equilibrium constant, Keq, is interpreted to be reflective of not only the 
amount of unbound resolving agent present in solution as a function of time, but also identifies 
which enantiomer would be present in excess.  As stated previously, the selectivity of the agent 
will depend in part not only upon the structural architecture of the resolving agent, but also the 
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 medium in which it functions.  Inherent changes in the agent’s selectivity are anticipated due to 
the structural modifications made to the agents in these experiments.   
In order to present a general explanation for the behavior of the measured Keq, the 
following assumptions and experimentally measured parameters are employed.  These 
statements are applied to all families of resolving agents used in this series of experiments. 
  
• Ibuprofen is soluble at the specified operating conditions as shown by Khundker 
and coworkers and experimentally verified. (29) 
• The resolving agents are soluble at the specified operating conditions as was 
shown in Chapter 7. 
• It is initially assumed that the dominant equilibrium reaction is the formation of 
an ion pair. 
• Since precipitation was not visually observed in these experiments, Equation (8-8) 
is employed to calculate Keq. 
• The formed salt complexes undergo minimal dissociation into its native starting 
materials as previously described in the experimental section. 
 
Comparing the data from Figures 43, 44, and 45 two distinct trends are observed.  First, it 
is evident by comparing the trend lines in these graphs that the relative value of the equilibrium 
constant appears to stabilize in the range of 5 to 30 minutes.  Faster equilibration times are 
observed with the resolving agents that exhibit higher solubility, i.e. silicone functionalized, at 
the operating conditions.  It may be inferred in this case that the time required to reach the 
observed equilibrium is highly dependent upon the rate at which the agent dissolves into the bulk 
 111
 CO2 phase.  Here, the forward and reverse reaction rates of solution present another potential 
equilibrium reaction.     
Also shown in Figures 43, 44, and 45 is the relatively large values for Keq within the first 
15 minutes of the experiment.  According to Equation (8-8), a large value of Keq is reflective of a 
large concentration of ibuprofen present as its complexed salt.  This particular effect observed in 
the graphs, however, is not attributed to salt formation in the initial time period of the 
experiment.  A more plausible explanation, rather, is that during this time period the dissolution 
of ibuprofen into the bulk CO2 phase is still occurring.  An artificially low free acid 
concentration would be measured, thus producing a large value for Keq.  Therefore, Equation (8-
8) cannot be properly applied to this initial phase since other physical processes, for example, 
solubilization of reactants and their associated rates, appear predominant. 
If precipitation of the salt complex were to occur, the equilibrium model used for this 
reaction system would produce overestimated values of Keq due to the exclusion of the 
precipitate term.  During experimentation, however, no visible precipitate was observed.  This 
implies that either precipitation did not occur to any noticeable extent during the time period of 
the experiment, the solution was dilute enough so that no visible precipitation would be visually 
seen, or that salt did not form.  The later is ruled out simply because variations in Keq occurred 
with time.   
If precipitation were occurring at a significant rate, than a decrease in Keq as a function of 
time would be expected.  As shown in Figures 43, 44, and 45 this effect is not observed and 
instead a consistent value of Keq is shown, supporting the assumption that the rate of 
precipitation is considerably much slower than the relative measurement of equilibrium.  
According to Freiser and Fernando and Nielsen there exists a slow equilibration of solid and 
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 solute during precipitation phenomena, with the rate of precipitation characterized by a period of 
induction. (80, 85 )  During this process, nucleation is occurring, and the rate at which this process 
occurs is concentration and solubility dependent.  Generally, the higher the concentration of salt 
formed and the less soluble in its solvent medium, the faster the rate of precipitation. (85)  For this 
qualitative analysis, then, these anticipated heterogeneous systems may be then treated as 
homogeneous since precipitation phenomena does not appear to provide a significant 
contribution to the measurement of Keq.  
The silicone functionalized quinine resolving agent as shown in Figure 44 also exhibits a 
stabilization of Keq over time.  It appears with this resolving agent that equilibration occurs much 
faster as compared to the fluoroalkylated agents.  The rate of solubilization of this agent is likely 
much faster as compared to the fluoroalkylated agents due to the much higher solubility of the 
silicone derivatized resolving agent in CO2 as shown in Figure 34 of Chapter 7.  In addition, at 
the conclusion of the experiment where t=120 minutes, the average value for Keq for the silicone 
based agent was higher than that for the fluoroalkyl based agent, indicating that this particular 
agent was able to more efficiently bind ibuprofen. 
Interestingly, the fluoroalkylated quinidine resolving agent produced measured 
equilibrium constants one order of magnitude higher than either the fluoroalkyl or silicone 
functionalized agents with its apparent time to reach equilibrium consistent with the fluoroalkyl 
derivatized quinine.  According to this data, the quinidine analogue performed superior in its 
ability to bind ibuprofen in comparison to the other two agents.  Structurally, the agents in this 
family exhibit significant differences not only by tail character and placement, but also 
stereochemically.  Quinidine is the chiral inverse of quinine.  These results emphasize the 
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 importance of resolving agent architecture in terms of the ability of a bulky molecule, such as 
ibuprofen, to efficiently bind to the modified agent and maintain a stable salt complex.   
One other point to note is the large error associated with the experimental results.  This is 
in part attributed to the method of analysis and the experimental setup.  In terms of the method of 
analysis, the analytical method used to measure the concentration of ibuprofen does so on a 
milligram scale and large differences in concentration may result from small changes in the 
quantity of ibuprofen collected.  For example, upon examining the average Keq for the three 
different agents in this family, there is almost an order of magnitude difference.  The actual 
quantity of ibuprofen loaded into the cell differs by 0.01g between the three sets of experiments.  
Optimally, an in situ analytical technique would preserve mass in the analysis, however, a high 
pressure on-line instrument was not available. 
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Figure 43  Equilibrium Data for the Fluoroalkyl Functionalized Quinine 
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Figure 44  Equilibrium Data for the Silicone Functionalized Quinine 
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Figure 45  Equilibrium Data for the Fluoroalkyl Functionalized Quinidine 
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 The second observed trend concerns the selectivity of the agent.  As shown from Figures 
43, 44, and 45 only the fluoroalkyl functionalized quinine exhibited any degree of selectivity 
among the three resolving agents in this family, though this difference in Keq remains relatively 
small.  This experimental result is contrary to molecular modeling results presented in Chapter 4.  
From the theoretical calculations, it was predicted that the silicone functionalized quinine would 
retain the greatest degree of selectivity.  As compared to the fluoroalkyl analogue, the silicone 
tail was placed at a position removed from the chiral secondary alcohol.  This alcohol group 
functions as a source of hydrogen bonding, which is a critical point for chiral discrimination.  
The fluoroalkylated analogue, however, was derivatized at the chiral secondary alcohol to form 
an ester linkage and, thus, theoretically reduced its ability to hydrogen bond.  
 The fluoroalkyl functionalized quinidine, as shown in Figure 45, exhibited no selectivity.  
This result is consistent with molecular modeling studies presented in Chapter 4.  As compared 
to quinine, not only are functional group and/or tail placement critical, but also the spatial 
configuration.  As stated previously, complexation of ibuprofen’s carboxylic acid group is 
assumed to occur at the amine located in the bicyclic portion of the molecule.  Due to the 
bulkiness of the molecule, molecular motion is limited and thus the spatial configuration of those 
functional groups that participate in complexation through hydrogen bonding, for example, must 
be strictly defined for chiral discrimination to take place. 
It cannot be concluded exclusively that the observed loss of selectivity of these agents is 
strictly attributed to chemical modification, but rather the solvent system may also play a 
significant role.  The selectivity that was observed in a polar organic medium was not evidence 
in carbon dioxide, thus proving carbon dioxide an inferior substitute.  The salt complexes formed 
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 from these agents in CO2, therefore, will have to be separated as a function of their phase 
behavior alone. 
 
 
 
8.3.2 The Polyperfluoropropylene Oxide Derivatized L-lysine (Krytox) Family 
 
 
 
The next series of equilibrium data involve resolving agents that contain L-lysine as their 
chiral discriminator.  In this family, L-lysine has been derivatized with a polyperfluoroether tail 
containing 14 repeat units (MW ~ 2500).  These agents possess the ability to form soluble salt 
complexes and, thus, a homogeneous reaction system.  Any possibility of precipitation of the 
resultant salt complexes is not anticipated to occur due to the significantly higher solubility of 
the modified resolving agents as compared to those in the quinine family.  The equilibrium data 
for the three agents in this family are shown in Figures 46, 47, and 48.   
Contrary to that observed for the quinine family of agents, it can be clearly seen that 
equilibrium is established within 15 minutes for only one of the agents, namely the N’-
polyperfluoroether agent shown in Figure 46.  The other two agents, shown in Figures 47 and 48, 
exhibit inconsistent Keq as a function of time for the entire experimental duration.  The operating 
pressure of the system is well above that of the cloud point pressure for these agents.  It is 
expected, then, that solubilization of the starting materials occurs quickly and equilibrium would 
be readily established.   
Unlike the behavior exhibited by the quinine family of agents, this data shows an increase 
in Keq as a function of time, until a maximum is reached and either stabilizes or slightly begins to 
decrease.  This decrease in Keq, though difficult to discern because of the large error involved, 
may be due to a slight dissociation of the salt complexes, which would introduce another kinetic 
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 parameter to the reaction system.  Unfortunately, these types of competing kinetic effects are 
difficult to discern from the present data, since the experimental setup was not designed to 
quantitatively evaluate individual kinetic mechanisms.  
For the agents shown in Figures 47 and 48, the polyperfluoroether tail appears to 
significantly interfere with the binding capability of its head group.  The polyperfluoroether tail 
is not only very flexible about its single bonds, but also significantly longer than any of the 
“CO2” philic tails placed on the native agents.  This tail has the ability to twist and wrap about 
the head group, which would be advantageous for solubilization.  In other words, possessing the 
ability to mask the polar portion of a molecule with a “CO2 philic” structure has the potential to 
improve and maintain solubility at lower pressures.  This spatial configuration, assuming that it 
is the lowest energetic configuration, may make it difficult for ibuprofen to truly bind to the head 
group if a bulky tail obstructs its pathway.  The agent shown in Figure 46, however, exhibits a 
stable Keq as a function of time.  The site of complexation for this agent would occur at the α 
amine, which is located adjacent to the chiral carbon and possibly less accessible to the flexible 
tail.   
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Figure 46  Equilibrium Data for N’-(Polyperfluoroether)-L-Lysine  
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Figure 47  Equilibrium Data for N-(Polyperfluoroether)-L-Lysine Methyl Ester  
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Figure 48  Equilibrium Data for (Polyperfluoroether)-L-Lysine With Alkyl Spacer 
 
 
 
Interesting trends are observed for the selectivity of these agents.  Examining Figures 46, 
47, and 48 the average Keq for each agent shows a consistent preference for the R(-) enantiomer.  
This is contrary to the molecular modeling studies as presented in Chapter 4.  The theoretical 
calculations indicate that there exists a slight preference for the S(+) enantiomer and that when 
translated into enantiomeric excess, there should be no discernable selectivity for all of the three 
agents in this family as a whole.  Molecular modeling results also predicted that the N-
polyperfluoro methyl ester derivative would provide the greatest selectivity of the three agents, 
though this selectivity is minimal.   
Evaluating the average trend line for Keq in Figure 47, it is shown that not only does the 
selectivity decrease as a function of time, but also Keq.  A reduction in Keq indicates that the 
concentration of free ibuprofen is increasing, leading to the belief that this particular agent is not 
effectively binding ibuprofen.  The trend lines for the other two derivatives, as shown in Figures 
46 and 48, indicate that a greater degree of selectivity is observed with these agents.  The 
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 polyperfluoroether derivative suggests that after 80 minutes, the agent exhibits a preference for 
the S(+) enantiomer, which is consistent with molecular modeling results.  The N’-
polyperfluoroether derivative in Figure 46, however, maintains a minimal preference for the R(-) 
enantiomer.  Due to the large standard deviation calculated for this experimental set, however, it 
is difficult to discern if any selectivity exists.   
 From an operational standpoint, these agents would not be practical to use.  Since the 
solubility of the agent as a whole is strongly dictated by the contribution of the tail, separation of 
the native agent and product would be difficult.  As stated previously, the salt is also a soluble 
component of the reaction system and its solubility is also anticipated to be very similar to the 
derivatized agent.  Without kinetic information, it is not obvious how separate factors influence 
the reaction itself.  For example, it is not obvious how effectively ibuprofen binds to the agent 
itself or if and to what extent ibuprofen undergoes secondary reactions, such as dimerization.   
 
 
 
8.3.3 The Perfluoro-2,5,8-trimethyl-3,6,9-trioxidedodecanoyl fluoride Derivatized   
Lysine (Lancaster) Family 
 
 
 
Another family of agents that possess lysine as the chiral discriminator is presented in 
Figures 49, 50, and 51.  In this family, lysine has been derivatized with a short chain 
perfluoroether tail (2 repeat units) at the same positions as the polyperfluoroether (Krytox) 
modified agents previously discussed.  These agents also form soluble complexes, so a 
homogenous system results from the reaction of the resolving agents and ibuprofen. 
Comparing the data from Figures 49, 50, and 51 an inconsistent trend is again observed 
with regards to the time required to reach equilibrium.  For example, it may be noted that in 
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 Figures 49 and 50, equilibrium has been reached at approximately 15 minutes.  The trend line in 
Figure 51, however, is less discernable. To be able to distinguish whether the causes of these 
deviations are related primarily to a reaction system in which each species is highly soluble or 
related to the natural error of the sampling/measurement technique, a comparison to the previous 
polyperfluoroether (Krytox) based analogues may be made.  For example, the inability to show a 
relatively constant Keq with time is a feature that both agents have in common.  However, this 
appears to be inconsistent within analogues.  For example, the N’-(polyperfluoroether)-L-lysine 
(Krytox) derivative was the one agent in that family that appeared to establish equilibrium.  In 
this family of agents (Lancaster), however, both the N-(perfluoroether)-methyl ester and N’-
(perfluoroether) derivatives appeared relatively stable.  Interestingly, the perfluoroether 
derivative of both families failed to establish equilibrium and the same cross over of the trend 
lines is evidenced.  However, the perfluoroether (Lancaster) agent exhibited a preference for the 
R(-) enantiomer instead of the S(+).  Though a lack of consistency is shown between both 
families of perfluorinated modified agents, the trend lines exhibit a similar pattern.   
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Figure 49  Equilibrium Data for N’(Perfluoroether)-L-Lysine 
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Figure 50  Equilibrium Data for N-(Perfluoroether)-L-Lysine Methyl Ester 
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Figure 51  Equilibrium Data for (Perfluoro)-L-Lysine with Alkyl Spacer 
 
 
In terms of selectivity, slight deviations in the trend lines from the polyperfluoroether 
(Krytox) analogues are again observed for this family of agents.  In Figure 49, a slight preference 
of the N’-perfluoroether (Lancaster) derivative for the S(+) enantiomer of ibuprofen is observed.  
This result remained consistent as a function of time.  In comparison to its polyperfluoroether 
(Krytox) analogue, the result is similar except that the polyperfluoroether (Krytox) analogue 
showed a preference for R(-) enantiomer.  A rational explanation for why the polyperfluoroether 
(Krytox) analogue exhibited a preference for the opposite enantiomer is unknown.   
The N-perfluoroether methyl ester (Lancaster) analogue in Figure 50 exhibited no 
preference for either enantiomer.  Interestingly, the third (Lancaster) agent - the perfluoroether 
agent, exhibited the same cross over effect as observed in Figure 48.  However, the switch in 
enantiomer selectivity occurred with the S(+) enantiomer being dominant in Figure 51 and the 
 124
 R(-) enantiomer in Figure 48 at the conclusion of the experiments.  Experimental error may be 
one plausible explanation and expanding the number of test sets may reflect a different behavior.  
Another possible explanation may be attributed to the sensitivity of the conformation of the 
binding pocket.  Synthetic conditions may have altered the configuration of the lysine head 
group that might impart a slight sensitivity for the R(-) enantiomer.  Qualitative polarimetry 
studies indicated, however, that for the polyperfluoroether (Krytox) derivative, the positive sign 
of the rotation of light indicated no change in the chiral configuration of the lysine head group. 
Molecular modeling studies for this family of agents indicated that no selectivity should 
be observed for the N-perfluoroether methyl ester and the N’perfluoroether derivatives.  The 
perfluoroether derivative exhibited a slight degree of selectivity, however, the opposite 
enantiomer was predicted by the theoretical calculations.   
 
 
 
8.3.4  The Fluoroalkyl Derivatized Lysine Family 
 
 
 
The last set of equilibrium data is presented in Figure 52.  This series of resolving agents 
involved the derivatization of lysine with a fluoroalkyl tail.  As stated in Chapter 7, only one out 
the three agents in this family proved to be soluble within the testing limits of the apparatus.  
There are some notable observations to make concerning this agent.  The first is that equilibrium 
is readily established within 20 minutes as observed in Figure 52, and this time frame is 
consistent with the fluoroalkylated quinine and quinidine.  A relatively uniform trend line would 
indicate that the rate of precipitation is significantly slower than the observed reaction 
equilibrium.  Unfortunately, slow precipitation, in terms of a separation scheme, would be 
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 unfavorable due to the long time required for not only precipitation to commence, but also the 
settling time required to generate a substantial quantity of product.  
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Figure 52  Equilibrium Data for N-(Perfluorooctanoly)-L-Lysine Methyl Ester 
 
 
 
Another observation to note is that there appears to be relatively little differentiation 
between the two enantiomers.  Molecular modeling studies indicated a higher degree of 
selectivity for this agent, with the S(+) enantiomer favored.  Lysine, itself, is not a very highly 
selective agent in CO2 or in a polar medium as compared to the catalysts used for the asymmetric 
synthesis of ibuprofen.  As reported by Tung and coworkers, the lysine ibuprofenate salts formed 
in a 95% ethanol/5% H2O solution form a eutectic point of approximately 55% to 65% of the 
S(+)-ibuprofenate salt predominating in ethanol. (31)  Thus, these salt complexes of the lysine 
family must be separated as a function of their phase behavior differences alone.  The 
experimental data for all agents presented in this chapter emphasizes that selectivity is highly 
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 dependent upon solvent type.  In this instance carbon dioxide does not serve as a conducive 
medium for these selective reactions, and the resultant ion pairs must exclusively be separated as 
a function of phase behavior differences. 
 
 
 
 
8.4  Conclusion 
 
 
 
A simplified experimental design and equilibrium model were developed in order to 
evaluate the dominant equilibrium that governs the reaction systems of interest.  It was initially 
assumed that the dominant equilibrium process was the ion pair formation between ibuprofen 
and the modified resolving agents.  From the data presented in this chapter, it was shown that the 
model used to fit the data did not predict the initial kinetic effects, such as the rates of 
solubilization, and this was shown as a large initial fluctuation in Keq.  Because precipitation was 
not visually evident, its inclusion into the model was neglected.  This simplification fit the data 
well as long as a stable system was observed.  The instability in certain reaction systems, 
particularly evident with the perfluoroether derivatized agents, failed to be explained by the 
equilibrium model.  Thus, it can be concluded that the model used was too simple in its origins 
and a more complex model, incorporating multi-equilibria fitted to accurate kinetic parameters is 
required. 
Under the assumption that ion pairing does occur, this experimental design provides a 
rough comparison to the molecular modeling results.  These theoretical calculations assumed that 
the molecule exists at its optimum bond lengths and angles within a vacuum.  Thus, solvent 
effects, packing forces, and other secondary influences such as intermolecular interactions are 
 127
 neglected.  Table 9 below lists the resolving agent and whether molecular modeling’s qualitative 
prediction was correct.  Upon examination of the table, molecular modeling proved to be 
approximately 60 % on target.  In terms of exclusively predicting the selectivity of the agent, 
though, molecular modeling proves to be an inferior technique due the lack of solvent and solute 
interaction present in the model.  In addition, its usefulness as a comparative method was 
qualitative at best due to the high experimental errors encountered within the data sets.  The 
utility, then, of molecular modeling for this research project is to serve as a screening tool for 
candidate agents and it has proven its utility for these purposes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128
  
 
 
 
Table 9  Comparison of Molecular Modeling and Experimental Results 
 
 
Resolving Agent 
Consistent with Molecular 
Modeling Result 
 
Fluoroalkyl Functionalized Quinine  
Fluoroalkyl Functionalized Quinidine √ 
Silicone Functionalized Quinine  
N’-(Polyperfluoroether)-L-Lysine √ a 
N-(Polyperfluoroether)-L-Lysine Methyl Ester √ a 
(Polyperfluoroether)-L-Lysine with Alkyl Spacer √ a 
N’-(Perfluoroether)-L-Lysine √ 
N-(Perfluoroether)-L-Lysine Methyl Ester √ 
(Perfluoroether)-L-Lysine with Alkyl Spacer √ 
N-(Fluoroalkyl)-L-Lysine Methyl Ester  
a)  error bars indicate no significant degree of selectivity, while the trend line indicates 
preference for the opposite enantiomer as predicted by molecular modeling 
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 9.0  ENANTIOMERIC RESOLUTION OF RACEMIC IBUPROFEN 
 
 
 
 
9.1  Design of a Separation System 
 
 
 
The goal is to develop a separation system, in which the enantiomers of ibuprofen can be 
resolved in the form of their diastereomeric complexes.  Racemic ibuprofen is soluble in CO2 at 
30 oC as shown from experimental phase behavior measurements in Figure 53, which is 
consistent with the results of Khundker and coworkers. (29)  Use of the resolving agent in either 
the unadulterated or functionalized form allows us to examine several types of separation 
strategies.  For example, lysine is essentially insoluble in CO2 up to the pressure limitations of 
our instruments, and thus, its native form cannot be used to separate ibuprofen in CO2.  For the 
case of either quinine or S(+)-phenylglycinol, however, the unaltered resolving agent exhibits 
measurable solubility in CO2, but complexes formed from reaction of either of these agents and 
ibuprofen are essentially insoluble in CO2, as determined from experimental measurements using 
the W.B. Robinson Cell.  Finally, in the case of lysine or quinine which have been functionalized 
with fluoro and/or silicone functional groups, both the resolving agent and the resultant complex 
formed from ibuprofen are soluble in CO2 under certain conditions of temperature and pressure. 
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Figure 53  Phase Behavior of Racemic Ibuprofen, Ketoprofen, and 
            Naproxen 
 
 
 
 
9.2  Heterogeneous Reaction Environment 
 
 
 
Based upon the phase behavior of the various agents and the diastereomeric complexes 
formed from them, we have evaluated 3 methods of separation.  These methods involve 
heterogeneous, homogeneous, and homogeneous mixed agent reaction environments.  The first 
method that will be described proposes that if we charge the reactor with, for example 
unmodified quinine and racemic ibuprofen at conditions where all of the ibuprofen would 
dissolve, we might expect that as quinine dissolves into solution, diastereomeric salts would 
form in quantities dependent upon the selectivity of quinine. 
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 One of the primary advantages of performing an enantiomeric separation by this method 
is that the chiral agent is used in its native form.  Thus, the inherent selectivity of the agent is 
preserved.  Preservation of this selectivity, however, is only advantageous if selectivity is not 
greatly influenced by the solvent type.  In this instance, the change in solvent polarity from 
ethanol to CO2 is significant.  As shown in Chapter 8, any selectivity of the modified resolving 
agents was absent in the CO2 medium.  Thus, it is anticipated that some decrease in selectivity 
for the native agents will also be experimentally observed. 
Kinetic effects are also expected to contribute to the observed selectivity.  The limited 
solubility of the resolving agent creates a reaction system that is highly dependent upon the rate 
at which the agent enters into solution.  In this manner, the separation becomes a reactive 
separation which incorporates the elements of selectivity and limited solubility at static operating 
conditions. (87)  
For this set of experiments S(+)-phenylglycinol and quinine were chosen as the test 
agents for racemic ibuprofen due to the following characteristics for each agent. 
 
• Good selectivity for both of these agents was observed in organic solution.  A 
diastereomeric crystallization was performed in ethanol according to the procedure 
outlined by Tung and coworkers. (31)  The remaining liquor was separated from the 
solids and analyzed for free ibuprofen content according to the procedure described 
in Section 8.2.  A peak area ratio of approximately 3:1 R(-) to S(+) was obtained for 
both of these agents.  
• These compounds are established resolving agents for racemic acids. 
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 • Both agents exhibited a qualitative degree of solubility in supercritical CO2 as 
determined from preliminary phase behavior measurements.  The concentration of 
each agent that was dissolved in solution was estimated at 0.002 mole% and 0.005 
mole % for quinine and S(+)-phenylglycinol, respectively. 
 
 
 
9.2.1 Experimental 
 
 
 
In these experiments, 0.1 mole % of racemic ibuprofen is loaded into a prewarmed high 
pressure cell, as well as an equimolar amount of (a) S(+)-phenylgylcinol or (b) quinine.  The cell 
is then charged with CO2 to a pressure of 5800 psi and continually stirred.  Samples of the fluid 
phase are withdrawn at designated time intervals.  If formed, precipitate will settle to the bottom 
of the reactor unit.  The base of the reactor was specially machined in the shape of a smooth 
funnel so that precipitate is directed to the bottom of the reactor.   
Samples were analyzed by a Hewlett Packard Series II 1090 HPLC unit using a Chiracil-
ODH (Chiral Technologies) chiral column.  The mobile phase consists of 98% hexane: 1.9% 2-
propanol: 0.1% TFA, and the analysis was run with a flow rate of 0.8 ml/min at 38°C.  The run 
time for sample analysis was 8 minutes.  The percent enantiomeric excess (%EE) was calculated 
as follows 
  
          %EE =
R
S
−1    
R
S
+1    
x100                         (9-1) 
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 where R is the peak area for the R(-) enantiomer of ibuprofen and S is the peak area for the S(+) 
enantiomer of ibuprofen. 
The results of these experiments for both agents are shown in Figures 54 and 55.  S(+)-
Phenylglycinol performed poorly, exhibiting only a modest 17% enantiomeric excess after 24 
hours in supercritical conditions (T = 35 oC).  No significant enantiomeric excess was evident 
when the same agent is run in liquid CO2.  These results are contrary to what had been observed 
in ethanol, and again carbon dioxide does not appear to function as a reaction medium conducive 
to selectivity for this native agent.  Evidence that complexation was occurring was obtained from 
measuring the concentration of free ibuprofen as a function of time.  The reactor was loaded with 
an initial charge of 0.1 mole % of ibuprofen.  After 30 minutes, the concentration of free 
ibuprofen was reduced to 0.006%.  At the conclusion of the experiment greater than 99% of the 
ibuprofen was no longer available in its free acid form. 
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Figure 54  % Enantiomeric Excess:  S(+)-Phenylglycinol as Resolving 
         Agent (rt = 25 oC) 
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Figure 55  % Enantiomeric Excess: Quinine as Resolving Agent (rt = 22 oC) 
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  If the agent’s selectivity was truly a dominant parameter for this type of separation, then 
it is expected that the highest enantiomeric excess would be observed in the initial phase of the 
experiment.  This type of separation would mimic a kinetic resolution.  Instead, the highest % EE 
is observed towards the conclusion of the experiment at t = 24 hours (1440 min).  These 
observations lead to the conclusion that the selectivity of S(+)-phenylglycinol is severely 
depressed in a carbon dioxide environment.   
  In addition, the measurement of higher %EE at longer reaction times also gives an 
indication that the %EE is a result of solubility differences between the formed complexed salts.  
Precipitation was not visually observed within the first 6 hours, but lack of a visual observation 
does not necessarily preclude any precipitation that might have occurred within the 24 hour time 
period.  Samples of the fluid phase only are taken and are filtered in line prior to loading in the 
sampling value.  The fact that 99% of the ibuprofen was bound indicates that complexation did 
occur and whether the complexes precipitated out, were soluble at their specific concentration, or 
were simply dispersed in the fluid phase by the action of the stirrer is unknown. 
Quinine exhibited a measured 39% enantiomeric excess under the same operating 
conditions, which is comparable to the measured 58 % EE in organic solution, and is a marked 
improvement over the results obtained for S(+)-phenylglycinol.  In addition, this particular agent 
appeared less sensitive to differences between liquid and supercritical conditions.  Similar to 
S(+)-phenylglycinol, greater than 90% of the free acid form of ibuprofen was bound by the 
conclusion of the experiment.  However, a concentration of 0.006 mole % ibuprofen in CO2 was 
not realized until 180 minutes versus 30 minutes for S(+)-phenylglycinol.  This result would 
indicate that either quinine does not enter the bulk fluid phase at a rate similar to S(+)-
phenylglycinol, the reaction rate for quinine and ibuprofen is much slower than S(+)-
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 phenylglycinol, side reactions are more predominant with the quinine agent system, or a 
combination of all these factors.  As discussed previously for S(+)-phenylglycinol, larger 
enantiomeric excesses were observed at longer reaction times again indicating a depression of 
selectivity and % EE being predominantly a function of variable phase differences between the 
two salts.  
 These two agents were also chosen to qualitatively compare the difference between the 
efficiency of binding of a primary and tertiary amine.  A comparison of these two agents gives 
insight into the effects of potential carbamate formation at operating conditions.  From the results 
reported above, each agent was capable of binding almost the complete stoichiometric ratio of 
ibuprofen, indicating that carbamate formation did not occur or did not preclude binding of the 
chiral agent to ibuprofen.  The worst case scenario would be reaction of CO2 with a primary 
amine.  Either the primary amine of S(+)-phenylglycinol does not bind with CO2 or ibuprofen is 
able to displace the CO2 group. 
 Because quinine exhibited reasonable enantiomeric excess at a 1:1 mole ratio with 
racemic ibuprofen, it was hypothesized that a 1:2 mole ratio of agent to ibuprofen would yield 
improved enantiomeric excess if selectivity were truly a dominant parameter in this type of 
separation scheme.  Ideally in crystallization, if only one of the salts crystallizes out of solution, 
then one half of the mole equivalent is required due to large differences in solubility of bound 
and unbound species if selectivity exists. (5)  As shown in Figure 56, the enantiomeric excess 
under the same test conditions was decreased.  This result supports the assertion from the 
previous experiments that agent selectivity for the unadulterated agents is severely attenuated 
and separation must primarily occur by phase behavior differences alone. 
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Figure 56  % Enantiomeric Excess: Comparison of 1:1 and 1:2 Mole 
          Ratio of Quinine to Ibuprofen 
 
 
 
9.2.2  Concluding Remarks 
 
 
 
Though this mode of resolution for the enantiomers of ibuprofen offers many process 
advantages, its functionality as a separation system is poor.  This poor performance is mainly due 
to the inability of the resolving agents in supercritical CO2 to effectively discriminate between 
the two enantiomers of ibuprofen.  The problem is also compounded by the poor solubility of the 
resolving agent, giving rise to other dominant kinetic effects.  The introduction of a polar 
modifier, such as methanol, could potentially aid in the solubilization of the agent and its 
resultant salt complexes.  This concept was effectively demonstrated by Eckert and coworkers.  
They formed two diastereomeric salts, (R)-(+)-α-phenethylammonium (R)-(-)-mandalate and 
(R)-(+)-α-phenethylammonium (S)-(+)-mandalate using (R)-(+)-α-phenethylamine as the chiral 
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 discriminator in polar organic media.  Interestingly, CO2 was added to the organic phase as an 
anti-solvent to precipitate one of the salts.  They were able to obtain %EE in excess of 90%. (88)  
The advantages of using a modifier in this scenario are 1) the potential increase in the rate 
of agent solubilization 2) the potential improvement in agent selectivity and 3) the enhancement 
of solubility differences between the diastereomeric salt pair.  These factors lead to a separation 
system more similar to the traditional crystallization schemes.  The drawback to using a 
modifier, however, is the introduction of an organic component to an organic free 
solvent/reaction medium.  These issues have led to a redesign of the resolving agent, which has 
resulted in the development of a homogeneous phase separation system.  Generation of a 
homogeneous mixture that includes salts, i.e. the reaction products of resolving agents plus 
ibuprofen, requires that we derivatize the resolving agents to enhance their solubility and thus 
that of the salts in CO2.  Consequently, we have functionalized those resolving agents under 
consideration with so called “CO2-philic” moieties (or “tails”).  This is the chemical equivalent 
of a bound co-solvent to enhance solubility. 
 
 
 
 
9.3  Homogeneous Reaction Environment 
 
 
 
In the previous section we described the results of experiments where a heterogeneous 
system (solution plus residual solid) was employed in an attempt to separate the enantiomers of 
ibuprofen in CO2.  By contrast, in this section we describe the results of a separation performed 
from an initially homogeneous mixture of ibuprofen, resolving agent, diastereomeric salt, and 
CO2.  As described in Chapter 8, the ability to separate the enantiomers of ibuprofen as a 
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 function of the agent’s natural selectivity was not evident.  The data experimentally measured in 
Chapter 8 is supported by the inability to obtain high %EE from the previous heterogeneous 
reaction system.  Thus, the separation of the enantiomers of ibuprofen must be performed strictly 
as a function of phase behavior differences alone.  
 
 
 
9.3.1  Resolving Agent Selection 
 
 
 
Whether a polar modifier or actual covalent modification of the resolving agent is the 
method of choice to create a homogeneous reaction/separation medium, the separation 
methodology is based upon a thermodynamic resolution.  As discussed previously, equilibrium 
conditions are established within a relatively short reaction time.  The reaction time is rapid 
enough so as to make a kinetic resolution improbable, especially with the current design of the 
operating system.    
Based upon the molecular modeling results presented in Chapter 4 and the measured 
equilibrium constants presented in Chapter 8, the fluoroalkylated quinine and lysine agents as 
shown in Figure 57 were selected for this series of experiments.  As described previously, use of 
either the perfluoro, polyperfluoro, or silicone modified agents wasn’t deemed sensible based 
upon the inherently high solubility of these compounds and their complexes, resulting in a more 
difficult separation.  Because the salt complexes are to be separated as a function of phase 
behavior alone, the fluoroalkylated agents have the advantage of poorer solubility. 
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Figure 57  Fluoroalkylated Quinine and L-Lysine Methyl Ester 
 
 
 
It was hypothesized that the salts formed from the complexation of ibuprofen and 
modified resolving agent might exhibit phase behavior patterns which are different from one 
another, and that those phase behaviors would be different from free ibuprofen and free resolving 
agent.  This was experimentally verified as shown in Figures 58 and 59.  Expanded views of the 
phase behavior of the individual salts are shown in Figures 60 and 61.  The data in Figures 58 
and 59 suggest that one can certainly separate the ibuprofenate salts from residual resolving 
agent and from free ibuprofen, but that a clean separation of the two salts may be challenging 
based on the fact that the maximum observable difference in solubility between the two salts is 
approximately 150 psi for the L-lysine based agent and 300 psi for quinine based agent.   
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Figure 58  Phase Behavior Diagram for Fluoroalkyl L-Lysine Resolving 
             Agent, Racemic Ibuprofen, and the Corresponding Ibuprofenate 
             Salts 
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Figure 59  Phase Behavior Diagram for Fluoroalkyl Quinine Resolving 
             Agent, Racemic Ibuprofen, and the Corresponding 
             Ibuprofenate Salt 
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Figure 60  Phase Behavior Diagram for Fluoroalkyl L-Lysinate Salts 
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Figure 61  Phase Behavior Diagram for Fluoroalkyl Quinine Ibuprofenate Salts 
 
 
 
9.3.2 Experimental Procedure 
 
 
 
Now that the phase behavior of the salt complexes for the two different resolving agents 
have been verified, experiments were conducted in order to assess an optimal starting 
concentration of the reactants in order to obtain a maximum separation.  Examination of Figures 
60 and 61 show that the phase behavior differential along the measured concentration ranges 
remained relatively consistent for the lysine based agent and slightly higher differentials at 
increasing salt concentrations for the quinine based agent.  It is expected then that the starting 
concentration of lysine based reagents should be independent of concentration, while variability 
would be expected with the quinine based reagents. 
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 These particular experiments were carried out at two different temperatures, namely 26°C 
and 35°C in order to examine any difference in employing a sub or supercritical reaction system.  
Typically, a 1:1 mole ratio of the resolving agent to ibuprofen is loaded into the high pressure 
cell, which is then charged with CO2 to a pressure of 5800 psi.  This pressure is above the phase 
boundary curves of each of the components, as shown in Figures 58 and 59.  In order to 
determine the optimal initial concentration, the pressure is lowered suddenly by 800 psi to 5000 
psi, the contents of the cell allowed to settle, and the solution sampled for the free and bound 
ibuprofen in the fluid phase using the reactor configuration as shown in Figure 32.  This 
procedure is repeated three times for each concentration evaluated. 
Once determining an optimal initial reactant concentration, fractionation experiments 
were performed.  These experiments comprised three cuts per experiment in order to determine if 
the ability to obtain higher %EE as a function of subsequent precipitation steps was obtainable.  
It was initially anticipated that the number of cuts required would be large due to the similarity in 
phase behavior between the diastereomeric salts.  The fractionation process was setup using the 
reactor configuration as shown in Figure 33. 
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Figure 33 Modified High Pressure Batch Reactor 
 
 
 
Typically for the fractionation process, the reactor is initially loaded with a 1:1 mole ratio 
of resolving agent to racemic ibuprofen to attain a concentration range of 0.025 to 0.06 mole %.  
The reactor is then charged with CO2, pressurized to 5800 psi, and stirred for 60 minutes.  The 
pressure is lowered via the sampling valve by a designated increment, typically 800 psi, and any 
precipitated material is allowed to settle for 30 minutes.  Material which remains soluble in CO2 
after the pressure quench is collected by flushing the reactor with pure CO2 (at the quench 
pressure) through the back pressure regulator and into a trap (Thar Designs) where the pressure 
has been lowered to 1200 psi.  The reactor is isolated, and the flush line is further washed for an 
additional 5 minutes.  The product from the trap is collected, weighed, and analyzed.  The reactor 
is then re-pressurized to the initial reaction pressure and stirred for 30 minutes.  The procedure of 
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 depressurization, settling, wash, and re-pressurization is repeated two more times to constitute an 
experimental test set. 
Samples were analyzed by a Hewlett Packard Series II 1090 HPLC unit using a Chiracil-
ODH (Chiral Technologies) chiral column.  The mobile phase consists of 98% hexane: 1.9% 2-
propanol: 0.1% TFA, and the analysis was run with a flow rate of 0.8 ml/min at 38°C.  The run 
time for sample analysis was 8 minutes.  The percent enantiomeric excess (%EE) was calculated 
as follows 
  
          %EE =
R
S
−1    
R
S
+1    
x100                        (9-2) 
 
where R is the peak area for the R(-) enantiomer of ibuprofen and S is the peak area for the S(+) 
enantiomer of ibuprofen. 
 
 
 
9.3.3 Results and Discussion 
 
 
 
The results using the fluoroalkylated quinine resolving agent are shown in Table 10.  
Three initial starting concentrations were evaluated based upon the least dilute to the most dilute 
according the concentration profile in Figure 61.  Results indicate that the more the dilute the 
solution, the higher the measured enantiomeric excess.  This is surprising, as the phase behavior 
in Figure 61 shows that the pressure differential between the phase boundary curves of the two 
salts broadens as the solution becomes more concentrated.  This result gives an indication that 
the collective phase behavior of the solution is not well represented by the phase behavior curves 
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 generated independently for these salts.  In addition, the results for liquid CO2 are significantly 
poorer than for supercritical CO2 as was also observed for the heterogeneous reaction system.  A 
smaller phase behavior differential for the salts at the lower temperature is assumed responsible 
for the measured decrease in enantiomeric excess.  Increasing the temperature is often an 
effective means to improve the phase behavior differential between two components. 
Based upon these preliminary results, fractionations were performed at 35oC and at an 
initial reactant concentration of 0.02 mole %.  The results of these tests are also shown in Table 
10.  The enantiomeric excess measured in each fractionation remained relatively consistent.  This 
result indicates that there is no significant dilution of the reaction products after fractionation.  
From the trap, approximately 10% of the original ibuprofen concentration was collected, which 
is consistent with the phase behavior for these salts.  Most material is expected to precipitate out 
due to a modest difference in solubility between the two salts. 
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Table 10  Fractionation Results for the Fluoroalkylated Quinine Resolving Agent 
 
 
DETERMINATION OF STARTING CONCENTRATION 
 
Mole % 
 
% Enantiomeric Excess 
              35 oC                      25 oC 
0.05 15.9 ± 6.9 0 
0.03 30.5 ± 12.7 7.28 ± 1 
0.02 46.0 ± 9.0 3.50 ± 1 
FRACTIONATION RESULTS 
 
Fraction 
 
% Enantiomeric Excess 
35 oC 
1 44.1 ± 8.3 
2 52.8 ± 22.2 
3 45.8 ± 12.8 
 
 
 
 The results for the fractionations performed with the fluoroalkylated L-lysine derivative 
are presented in Table 11.  Again, three concentration ranges were measured to determine the 
optimal starting concentration.  However, the most dilute concentration tested, 0.016 mole %, 
resulted in no detectable ibuprofen (within the UV detector limits of the HPLC).  Enantiomeric 
excess at the higher initial concentrations was slightly below that obtained with the 
fluoroalkylated quinine agent and was verified by separations.  Comparing the phase behavior of 
the two salts in Figures 60 and 61, the lysinate salts exhibited a smaller solubility differential 
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 than the quinine based salt complexes.  Therefore, smaller observed enantiomeric excess is not 
an entirely unexpected result. 
Fractionations were performed at 35oC and at an initial reactant concentration of 0.03 
mole %.  At 0.03 mole % enantiomeric excesses of at least 30% would be expected, however, % 
EEs over 20% were not realized.  According to Figure 60, a maximum solubility difference of 
150 psi between the salt complexes was measured.  With the current equipment design, a fine 
separation of 150 psi is improbable.  Interestingly, unlike the fluoroalkylated quinine agent 
whose enantiomeric excess is predictable from its phase behavior, the fluoroalkylated L-lysine 
produced an opposite result.  According to its phase behavior diagram, an enantiomeric excess 
with respect to the R(-) enantiomer of ibuprofen should have been observed since the R(-) 
enantiomer is the more soluble salt.  Instead, an enantiomeric excess in relation to the S(+) 
enantiomer was measured and is consistent with the molecular modeling predictions from 
Chapter 4 and the work of Tung and coworkers. (31) 
The phase behavior measurements for these salts were performed at room temperature.  
By raising the temperature to 35 °C, the solubility order of the salts may have been potentially 
inverted.  This effect has been documented with ibuprofen and L-lysine in a diastereomeric 
crystallization process.  At higher temperatures, the R(-) enantiomer, as a lysinate complex, and 
not the S(+) enantiomer preferentially precipitates from solution. (32) 
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Table 11  Fractionation Results for the Fluoroalkylated L-Lysine Resolving Agent 
 
 
DETERMINATION OF STARTING CONCENTRATION 
 
Mole % 
 
% Enantiomeric Excess 
              35 oC                      25 oC 
0.06 30.0 ± 2.7 8.6 ± 1 
0.03 34.0 ± 12.7 6.70 ± 1 
0.016 N/A N/A 
FRACTIONATION RESULTS 
 
Fraction 
 
% Enantiomeric Excess 
35 oC 
1 19.8 ± 12.2 
2 9.6 ± 2.4 
3 21.4 ± 12.7 
 
 
 
9.3.4  Concluding Remarks 
 
 
 
This series of experiments has shown that measurable enantiomeric excess may be 
obtained by complexation of a chiral agent to the enantiomers in a racemic mixture with direct 
separation of the resultant salts.  The disadvantage of this method, however, is the poor yield.  In 
order to optimize the separation process, then, yield must be improved while maintaining a 
desirable enantiomeric excess.  In order to realize that goal, the phase behavior of the resultant 
salts must differ substantially.  It is hypothesized that diastereomeric salts formed from the same 
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 chiral agent will not give the desired phase behavior difference required for better yield in a CO2 
environment.  Instead, salt complexes formed from at least two chiral agents, whose solubility 
varies considerably, may produce the desired outcome.  The next section of this thesis briefly 
describes a preliminary investigation of multi-agent separations. 
 
 
 
 
9.4  Mixed Agent Reaction Environment 
 
 
 
The use of a single agent and pressure variations to resolve racemic ibuprofen produced 
preliminary results for %EE that are promising, yet the yields per fractionation were low.  This is 
primarily because the phase boundary curves for each diastereomeric salt are quite close to each 
other in P-x space.  When examining the phase behavior and selectivity of the various 
functionalized resolving agents, however, we observed that it might be possible to achieve both 
greater purity and higher yield through the use of a mixed agent system.   
 Unlike the previous method of separation, which was based on the resultant phase 
behavior of the salts alone, this mode of separation is surmised to be dependent upon not only the 
phase behavior of the salts, but also any limited competitive binding by the resolving agents.  It 
is hypothesized that one agent will exhibit a small, preferential affinity for one enantiomer, 
leaving the complimentary agent the remainder of the ibuprofen to bind.  In addition to 
selectivity if any exists, the phase behaviors of the resultant salts must differ appreciably in order 
to efficiently separate the two enantiomers.  This method, in theory, would prove advantageous 
over the use of single agent resolutions as discussed in the previous section. 
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 9.4.1  Results and Discussion 
 
 
 
The following resolving agents as shown in Figure 62 were chosen for a mixed agent 
enantiomeric separation based upon the large difference in solubility between them (> 1000 psi) 
and their natural, albeit minimal specificity for the enantiomers of ibuprofen as shown in Tables 
7a-7d and in Chapter 8. 
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Figure 62  Derivatives Chosen for Mixed Agent Separation 
 
 
 
The silicone modified quinine derivative was chosen because it retained the greatest 
theoretical and apparent selectivity in carbon dioxide of all agents tested.  
Polyhexafluoropropylene oxide L-lysine modified at the alpha carboxy group was chosen as a 
control molecule because it showed no preferential selectivity to either ibuprofen enantiomer.  
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 Each of these two molecules were paired with a fluoroalkylated quinidine due to its apparent 
reduced preference for S(+) enantiomer of ibuprofen.  The same experimental procedures 
described in Section 9.3.2 for use with the single agents were followed, except that a 0.5 mole 
ratio of each resolving agent to ibuprofen was used.  The results for this series of experiments are 
shown in Figure 63.  The percent enantiomeric excess is reported in Figure 63 relative to the S(+) 
enantiomer. 
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Figure 63  Enantiomeric Excess Obtained for the Silicone Derivatized 
Quinine/Fluoroalkylated Quinidine and the  
                         Polyhexafluoropropylene oxide L-lysine/Fluoroalkylated   
                         Quinidine Mixed Agent Systems 
he maximum yield for either resolving agent pair reached no greater than 20 % EE.  
 explanations for this observed decreased in enantiomeric excess are outlined below.   
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 • All of the modified agents exhibited no selective behavior.  Thus, the anticipated 
competitive binding of ibuprofen did not occur. 
• The collective phase behavior of the mixed agent system does not exhibit the 
same or similar phase behavior distinctly associated with each individual species 
as shown in Chapter 7.  At equilibrium there would exist at least five species, two 
sets of salt complexes and CO2, assuming that all of the ibuprofen was bound.  
The more soluble salts of the diastereomeric salt pairs present greater difficulty in 
separation, because their phase behavior is not dictated by a contribution of the 
head and tail group.  Instead, the phase behavior is governed primarily by the tail 
alone. 
• Typical of diastereomeric salts, the formation of an unfavorable eutectic is 
possible. 
• Polyhexafluoropropylene oxide modified agent may promote a slight cosolvent 
effect.  Empirical demonstrations in lab have shown the solubility of materials to 
be greatly enhanced when operating equipment is contaminated with this material. 
 
Performing a mass balance on ibuprofen, it was evident that the goal of improved yield 
was reached.  Up to 65% of the more soluble resolving agent was recovered from the trap as 
compared to 10% with the single agent system.  However, this occurred at the expense of 
decreased enantiomeric excess. 
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 9.4.2  Concluding Remarks 
 
 
 
The mixed agent system presents the most viable approach to achieving good 
enantiomeric separations via diastereomeric ion pairing in supercritical carbon dioxide.  
Unfortunately, the most theoretically selective of the resolving agents, in this case, is also the 
most difficult to separate due to its high solubility in CO2.  What resulted was a separation of 
almost one half of the 50:50 mixture.  A highly selective agent is critical if this design is to be 
efficient.  In order to utilize a mixed agent system for fine separations, not only are less CO2 
“philic” substitutes are required, but also specialized agents capable of retaining selectivity in 
carbon dioxide.   
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10.0  RECOMMENDED FUTURE WORK 
 
 
 
The work, which has been presented in this thesis, provides fundamental information 
towards the development of a fine separation system for enantiomers as a function of their 
diastereomeric salts.  Preliminary fractionations indicate that separations performed in this 
manner result in moderate enantiomeric excess, but poor yield.  In order to increase not only the 
enantiomeric excess of the product but also recovery, an investigation into the nature of the 
resolving agent is required. 
The inherent drawback to the currently designed resolving agents is the fact that the 
solubility of the diastereomeric salts produced from the reaction of ibuprofen and chiral agent are 
largely governed by the solubility of the “CO2 philic” chain of the resolving agent.  
Compounding the difficulty in separation is also the fact that the individual salts do not exhibit 
independent phase behaviors in solution.  Rather they form eutectics, and the position of that 
particular eutectic dictates the maximum separation that can be achieved.  In order to achieve the 
desired separation, then, new research into chiral binding should be explored.  This thesis 
presents data which indicates that a non-chromatographic, non organic medium separation may 
be plausible.  The key is to improve upon the selectivity of the agent.  Potential avenues of 
resolving agent modification are outlined below. 
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 Resolving Agent Design 
Affinity Modulation 
Affinity modulation is a term to describe the development of a three party binding system 
for the purpose of enhancing the affinity of a ligand to its target molecule.  The technique was 
developed by Gerald Crabtree and Thomas Wandless at the Howard Hughs Medical Institute.  
The basic premise behind this technique is to increase (or is some cases decrease) the affinity of 
a ligand for its target molecule by “borrowing” a third specific binding surface. (73)  
 What would be required is actually an additional chiral bridge from ibuprofen to the 
native resolving agent.  The orientation of the chiral alcohol of ibuprofen and of a hydrogen 
bonding functionality of the resolving agent would define the ability of the third chiral bridge to 
form or not to form a ternary complex.  Considering some of the primary factors which influence 
phase behavior, which include molecular weight and polarity, the chiral bridge could be designed 
in such a way as to either produce a significant increase or decrease in CO2 solubility upon 
complex formation. 
 
Inorganic Selective Binding Agents 
The preferred route for the production of single isomer pharmaceuticals is chemical 
assymetric synthesis.  The primary advantage of this production route is that theoretically no 
waste, i.e. unwanted isomer, is produced and this presents a cost effective strategy for single 
isomer drug development.  The lesson learned from this form of pharmaceutical development is 
that there exists a growing pool of highly specific inorganic catalysts.  For example, in order to 
produce a compound with 99% EE, the catalyst used must exhibit a 200:1 preference for one 
enantiomer.  In a supercritical CO2 extraction scheme, preferential binding to one enantiomer 
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 may potentially impart large solubility differences, attributable to both a difference in molecular 
weight and solute- CO2 interactions.  This would allow for the extraction of one unbound 
enantiomer, since ibuprofen is a CO2 soluble material.  The catalyst in this case would not be 
utilized as a viable component in a reaction scenario, but rather as a means to selectively adjust 
the physical parameters of one of the enantiomers of ibuprofen in its racemic mixture. 
 
Molecular Modeling 
 A key component in the investigation of determining the optimal resolving agent for a 
supercritical CO2 extraction/fractionation system is the use of molecular modeling.  This 
technique serves a twofold purpose.  First, it functions as a laboratory time saving technique by 
allowing the investigator to construct and complex molecules.  As shown in this thesis, structure 
is a predominant factor in a molecule’s ability to dissolve in CO2.  Strain energy and geometrical 
evaluation are useful tools to screen individual candidates.   
 An in depth calculational design is required in order to construct a highly selective agent.  
This includes not only modeling the agent in vacu, but also in a CO2 solvent box.  Because CO2 
–solute interactions govern solubility, a more precise theoretical model of how these agents and 
ibuprofen would behave in response to each other is vital.  The key to efficiently separating these 
enantiomers from their racemic mixture in a supercitical carbon dioxide medium is phase 
behavior.  The more information which can be derived about CO2 and structure relationships, the 
more successful a resolving agent system may be chosen and applied. 
 The second function of molecular modeling is its utility as a method for theoretical model 
development.  Predicting the solubility of molecules in carbon dioxide is an area of research, 
which has been in progress for more than twenty years.  In addition, the force fields, which are 
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 used for calculational design, are consistently improving and incorporating more accurate 
property descriptions of carbon dioxide.  Developing a theoretical model for enantiomeric 
resolutions of the nature reported in this thesis is not only innovative, but would provide valuable 
information in relation to alternative means of racemic resolution in non-organic media. 
 
Reactor Design 
 Ideally, the standard batch reactor is useful for fractionation experiments.  In practice, 
however, there is room for improvement in the current fractionation high pressure setup.  Areas 
of improvement include better control of the downstream vent for collection of dissolved 
materials.  The maximum amount of total product recovery with the current reactor system was 
approximately 63%.  Material was potentially lost in deposition in the lines and through the 
downstream trap vent line.  This includes redesign of the collection trap and tighter control of the 
vent pressure through the addition of a back pressure regulator.  
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